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ABSTRACT 
 
  Thyroid carcinomas are the most common endocrine 
tumors in humans, with a globally increasing incidence. 
Differentiated tumors, such as papillary (PTC) and follicular 
(FTC) thyroid cancers, are often curable with surgical resection 
and radiotherapy, whereas undifferentiated (anaplastic) thyroid 
carcinoma (ATC) is invariably lethal, due to the high 
invasiveness and insensitivity to radioiodine or 
chemotherapeutic treatment. Little is known about the 
molecular events that lead from the highly curable differentiated 
tumors to the very aggressive ATC. Through, a cDNA 
microarray analysis on different thyroid tumors we have 
isolated Twist1 as a gene upregulated in ATC. Twist1 is a 
highly conserved basic helix-loop-helix transcription factor that 
plays an important role in the development and progression of 
human cancer. Twist1 has been associated with epithelial-to-
mesenchymal transition (EMT) a key step during embryonic 
morphogenesis and in the progression of primary tumors toward 
metastasis. In this dissertation, we have shown that 
approximately 50% of ATCs upregulate Twist1 with respect to 
normal thyroids as well as to poorly- and well-differentiated 
thyroid carcinomas. Knockdown of Twist1 by RNA interference 
in ATC cells reduced cell migration and invasion and increased 
sensitivity to apoptosis. The ectopic expression of Twist1 in 
thyroid cells induced resistance to apoptosis and increased cell 
migration and invasion. To understand the molecular 
mechanisms through which Twist1 exert is biological effects in 
thyroid cancer cells, we have performed a microarray analysis 
of thyroid cancer cells ectopically expressing Twist1 in 
comparison to vector control cells. We have identified a set of 
20 genes involved in migration, invasion and apoptosis; 
expression levels of these genes changed upon Twist1 
overexpression or knockdown. Silencing of 5 of the 20 target 
genes reduced viability of thyroid cancer cells overexpressing 
Twist1. Thus, our data suggest that Twist1 plays a key role in 
determining malignant features of the anaplastic phenotype and 
identifies a set of Twist1 target genes that could be used as 
molecular target for the therapy of ATC. 
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1. BACKGROUND 
 
1.1 Thyroid tumors 
 
1.1.1 Morphological and clinical features of thyroid tumors 
 
  Thyroid carcinoma accounts for about 1% of all 
human cancers. The incidence of thyroid cancer has been 
steadily increasing worldwide over the last few decades, 
predominantly due to the increased ability to detect small 
papillary carcinomas (Hodgson et al. 2004; Jemal et al. 2010).  
  Thyroid tumors represent an heterogeneous group of 
neoplasms with distinctive clinical and pathological features. It 
can originate from follicular cells (~ 95%) or from calcitonin-
secreting C-cells (~ 5%). There are five major types of thyroid 
carcinoma divided in distinct classes: well-differentiated 
carcinomas, including papillary (PTC), follicular (FTC); poorly 
differentiated carcinomas (PDC); undifferentiated or anaplastic 
thyroid carcinoma (ATC) and medullary thyroid carcinoma 
(MTC). PTC and FTC account for about 80% and 10% of cases, 
respectively, PDC account for ~5%, ATC account for ~2% and 
MTC account for ~3% (DeLellis and Williams 2004; DeLellis 
2006; Kondo et al. 2006). These tumors differ noticeably in 
aggressiveness, ranging from well differentiated to ATC. 
  PTC is characterized by a branching (papillary) 
architecture and peculiar nuclear features, several variants are 
known (DeLellis, 2006). PTC is more frequent in women than 
men and affects patients of 20-50 years old. PTC can also occur 
in childhood as consequence of accidental or therapeutic 
radiation exposure. PTC present an indolent behavior, tendency 
to form metastasis to local lymph nodes and survival rate greater 
than 90% (Schlumberger, 1998; Kondo et al. 2006). Sometimes 
the disease may show an aggressive behavior and lose the 
ability to concentrate radioiodine. 
  FTC is characterized by follicolar cell differentiation 
in the absence of the diagnostic nuclear features of PTC. It 
mostly affects 40-60 years old patients with a female to male 
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ratio 3-4:1. Despite a higher frequency of distant 
haematogenous metastasis compared to PTC, most FTC patients 
can also be cured, with good long-term survival rate (Kondo et 
al. 2006). 
  PDC represent a small group of thyroid tumors. 
These tumors shows loss of structural and functional 
differentiation and, characteristically, show widely infiltrative 
growth, necrosis, vascular invasion and numerous mitotic 
figures (DeLellis, 2006; Pulcrano et al. 2007; Volante et al. 
2007). 
  ATC is the most aggressive thyroid tumor, and it is 
described among the most lethal human malignancies, with a 
median survival from diagnosis of ~3-6 months (Perri et al. 
2011). Despite accounting for only ~2 of all thyroid tumors, 
ATC is responsible for more than half of the deaths attributed to 
thyroid cancer. Clinically, these tumors usually present during 
the 6th to 7th decade of life as a rapidly enlarging neck mass that 
extends locally, compressing the adjacent structures and tends to 
disseminate both to regional nodes and to distant sites, including 
lung, pleura, bone and brain. Worse prognosis is associated with 
large tumor mass, distant metastases, and acute obstructive 
symptoms (Pierie et al. 2002, McIver et al.  2001). Current 
treatment of ATC has often only palliative purposes, particularly 
relief of airway compression, having little impact on patient’s 
survival (De Crevoisier et al. 2004). 
  MTC derives from the neuroendocrine C-cells of the 
thyroid. Sporadic disease accounts for 80% of cases; the 
remainder 20% of patients inherit MTC in the context of 
autosomal dominant multiple endocrine neoplasia type 2 
syndromes (MEN2A, MEN2B and FMTC). Sporadic MTC 
usually presents with palpable thyroid nodules in the 3rd-6th 
decades of life. Total thyroidectomy is recommended for MTC 
patients. Clinical recurrence in the neck or in mediastinum is a 
common problem for MTC patients (Leboulleux et al. 2004, 
Cote and Gagel 2003). 
 
 
1.1.2 Risk factors of thyroid carcinomas 
 
Thyroid neoplasms are related to several risk factors that 
influence the incidence and mortality, including geographical 
area, the inter-individual variability, reduced iodine uptake and 
hormonal factors.  
  Radiation exposure is an important exogenous risk 
  9 
factor able to cause thyroid carcinoma. Indeed, after nuclear 
explosions of Hiroshima and Nagasaki and Chernobyl nuclear 
disaster, PTC frequency markedly increased in children exposed 
to radiations  (Ciampi and Nikiforov 2005). It is still unclear 
whether this particular occurrence in children is because the 
thyroid is most susceptible to radiation-induced damage in 
childhood or because children were exposed to contaminated 
milk or both (Williams 2002). The radiation associated to PTC 
typically belong to the solid-follicular variant, and are frequently 
positive for chromosomal rearrangements involving the RET 
proto-oncogene, as well as being more aggressive than other 
cancers not linked to radiation exposure (Williams 2002).  
  Recently, Antico-Arciuch and co-workers revealed a 
role for estrogens using a transgenic model of thyroid 
carcinogenesis (Antico-Arciuch et al. 2010).  
  A deficient dietary intake of iodine can result in 
increased proliferation of thyroid cells in the goiter. The 
incidence of FTC in iodine-deficient areas is significantly 
increased (Kondo et al. 2006). 
 
 
1.1.3 Genetic alterations in thyroid carcinomas 
 
  The genetic lesions associated to thyroid carcinomas 
can affect either proto-oncogenes (gain-of-function mutations) 
or tumor suppressor genes (loss-of-functions). These lesions are 
listed in Table 1. 
 
Table 1: Genetic alterations in thyroid carcinomas. 
 
Tumor Type Cell Type Molecular Lesion 
 
PTC Follicular cells 
 
-RET/PTC rearrangements 
-NTRK1 rearrangements 
-BRAF point mutation 
 
 
FTC Follicular cells 
 
-PAX8/PPARγ rearrangements 
-RAS point mutation 
 
 
PDC Follicular cells 
 
-RAS point mutation 
-PI3KCA point mutation or amplification 
 
ATC Follicular cells 
 
-TP53 point mutation 
-BRAF point mutation 
-RAS point mutation 
-TP53 point mutation 
-CTNNB1 point mutation 
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-PI3KCA/AKT point mutation 
 
MTC Parafollicular cells 
 
-RET point mutation 
 
 
 
 
Genetic alterations in PTC  
 
  Genetic alterations associated with PTC include 
chromosomal rearrangements targeting the RET or NTRK1 
genes, and point mutations in the RAS or BRAF genes. Involved 
genes encode proteins that signal along the mitogen-activated 
protein kinase (MAPK) pathway, and the genetic alterations 
targeting them result in MAPK pathway activation.  
  The RET (Rearranged during Transfection) proto-
oncogene is located on chromosome 10q11.2 and encodes for 
the tyrosine kinase receptor of growth factors belonging to the 
GDNF (Glial cell line-derived neurotrophic factor) family 
(Manié et al. 2001). Binding to the ligand in the presence of co-
receptors of the GFRα (GDNF family receptors α) family 
causes RET dimerization and autophosphorylation of tyrosine 
residues within its intracellular domain. Phosphorylated 
tyrosines become binding sites for signaling molecules 
containing phosphotyrosine-binding motifs (Santoro et al. 
2004). In the thyroid gland, RET is normally expressed at high 
levels in parafollicular C-cells, but not in follicular cells. By 
providing an active promoter, chromosomal rearrangements 
fusing the 3’ kinase-encoding portion of the RET gene with the 
5’ portion of heterologous genes, enable thyroid expression of 
the chimeric RET/PTC oncoproteins (Fusco et al. 1987; Grieco 
et al. 1990). Moreover, fusion with partner genes encoding for 
proteins possessing protein-protein interaction motifs results in 
RET/PTC ligand- independent dimerization and 
autophosphorylation. Breakpoints in the RET gene leave an 
intact kinase domain, and 11 autophosphorylation sites are 
maintained in RET/PTC oncoproteins. Phosphorylated Y1062, 
RET/PTC is able to bind SHC and FRS2, which recruit Grb2-
SOS complexes leading to the activation of the RAS-RAF-
MAPK cascade (Asai et al. 1996). Through Y1062, RET is also 
able to activate the phosphatidylinositol 3-kinase (PI3K)/AKT 
pathway (Segouffin-Cariou and Billaud 2000; Pelicci et al. 
2002; Frêche et al. 2005).  
  So far, at least 11 RET/PTC have been identified, 
formed by the RET fusion to different partners; RET/PTC1 and 
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RET/PTC3, resulting from fusion with the H4 (D10S170) 
(Grieco et al. 1990) and the RFG (NCOA4, ELE1 or ARA70) 
(Santoro et al. 1994; Borganzone et al. 1994) genes respectively, 
are the most prevalent variants. RET rearrangements are found 
in 20-40% of PTC, but the prevalence is significantly higher in 
patients with a history of accidental or therapeutic radiation 
exposure. RET/PTC1 is more frequently associated with classic 
PTCs and with the diffuse sclerosing variant; conversely, 
RET/PTC3 is more common in the solid variant and in PTC 
associated to ionizing radiations (Thomas et al. 1999). RET 
rearrangements appear to have a lower prevalence in the 
follicular variant compared to classic PTC. RET/PTC is able to 
induce transformation and dedifferentiation of cultured thyroid 
cells. RET/PTC-transgenics mice develop PTC, meaning 
RET/PTC oncogenes are able to initiate thyroid carcinogenesis 
(Powell et al. 1998). Moreover, RET/PTC is frequently detected 
in clinically silent papillary micro carcinomas, proving it can be 
an early event in thyroid tumorigenesis (Fusco et al. 2002).  
  Similar to RET, the NGF (Nerve Growth Factor) 
high affinity receptor NTRK1 (neurotrophic receptor-tyrosine 
kinase) gene may undergo oncogenic activation by 
chromosomal rearrangement. Such rearrangements are 
significantly less common in PTCs than the ones involving the 
RET gene (DeLellis 2006).  
  Activating point mutations in RAS, small GTPase, 
are quite uncommon in in the follicular variant of PTC (De 
Lellis 2006) 
BRAF is a serine-threonine kinase belonging to the RAF family 
(ARAF, BRAF, CRAF) of intracellular effectors of the MAPK 
pathway (Davies et al. 2002). Recruitment to the cell surface and 
binding to RAS in its GTP- bound state triggers RAF activation, 
which in turn phosphorylates MEK, causing sequential 
activation of downstream effectors of the MAPK cascade. 
Among the RAF family members, BRAF appears to have the 
highest basal kinase activity and is the most potent activator of 
the MAPK pathway. Activating point mutations within the 
kinase domain of the BRAF gene have been found in several 
tumor types, including melanoma and colorectal cancer (Davies 
et al. 2002). A thymine to adenine substitution at nucleotide 
1799 (T1799A), resulting in a substitution of a valine with a 
glutamic acid at residue 600 (V600E) of the protein, is the most 
common event; V600E and most other mutations within the 
kinase domain target either the activation loop or the ATP 
binding site (P loop). By disrupting the interactions between the 
activation loop and the P loop that hold the kinase in an inactive 
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conformation, these mutations cause BRAF constitutive 
activation. BRAF mutation represents the most common genetic 
event in PTC, occurring approximately in 45% of all cases 
(Xing 2007; Ciampi and Nikoforov 2005). Virtually, all the 
mutations in these tumors are V600E; other rare mutations, like 
point mutation K601E, insertion V599Ins, and the inversion of 
chromosome 7q fusing the kinase domain encoding-region of 
the BRAF gene with the AKAP9 gene, have been described 
(Carta et al. 2006; Ciampi et al. 2005). BRAF mutations are 
highly prevalent in classic and tall-cell variant PTCs, but similar 
to RET rearrangements, they are rarely found in the follicular 
variant (Xing 2007), again underlining the association of 
different mutations with specific thyroid tumor subtypes. The 
presence of BRAF mutations has been found to correlate with 
aggressive tumor behavior, tumor recurrence, decreased 
radioiodine concentration ability, failure to treat recurrent 
disease. Furthermore, BRAF mutation proved to be able to 
predict tumor recurrence (Namba et al. 2003; Riesco-Eizaguirre 
et al. 2006; Lupi et al. 2007). Thyroid-specific BRAF V600E-
transgenic mice develop papillary carcinomas that closely 
recapitulate the features of human PTC. These animals develop 
PTCs that not only share morphological features with their 
human counterpart, but also show characteristics of aggressive 
behavior and tendency towards progression to PDC. This 
suggests the involvement of BRAF mutation in PTC initiation 
and progression to PDC. Moreover, BRAF (V600E) mutation 
has been found in very early stages of PTC (Ugolini et al. 2007), 
further supporting its role in the initiation of these tumors.  
  Overall, genetic events involving RET, NTRK1, 
BRAF or RAS are found in the vast majority of PTC cases and 
rarely overlap in the same tumor (Kimura et al. 2003; Soares et 
al. 2003; Frattini et al. 2004), underlining the importance of 
MAPK pathway signaling-abnormalities in the pathogenesis of 
PTC. 
  Finally, point mutation or gene amplification of 
PI3KCA have been reported in a small fraction of PTC (Wu et 
al. 2005).  
  
 
Genetic alterations in FTC  
 
  FTC may develop through at least two different 
pathways, involving either RAS or the peroxisome proliferation-
activated receptor (PPAR) γ1. RAS point mutations are detected 
in about 50% of follicular carcinomas. Another subset of FTC 
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(~30%) harbor the t(2:3)(q12-13;p24-25) chromosomal 
translocation, which causes the fusion of the region encoding 
the DNA binding domains of the thyroid transcription factor 
PAX8 to the one encoding domains A-F of PPARγ steroid-
hormone receptor; the resultant fusion protein displays 
dominant- negative activity on wild-type PPARγ (Kroll et al. 
2000). As in PTC, point mutation or gene amplification of 
PI3KCA have been reported in some FTC cases (Wu et al. 
2005). 
 
 
Genetic alterations in PDC 
 
  PDC share genetic lesions in common with well-
differentiated carcinoma, consistent with the hypothesis of a 
multi-step model of thyroid carcinogenesis (Tallini 2002; 
Nikiforov, 2004). PDC are characterized by point mutations in 
RAS (Garcia-Rostan et al. 2005; Volante et al. 2007), 
amplification or point mutation in PI3KCA (Garcia-Rostan et al. 
2005). Moreover a significant fraction of PDC show point 
mutations of TP53 (Nikiforov 2004; Kondo et al. 2006). About 
30% of PDC harbor the V600E BRAF mutation, particularly 
those samples with morphological evidence of pre-existing PTC 
(Begum et al. 2004). Point mutations in exon 3 of CTNNB1 
have been reported in PDC and more frequently in ATC, but not 
in well-differentiated (Garcia-Rostan et al. 2001), suggesting 
that they might play a direct role in the dedifferentiation and 
progression to ATC. 
 
 
Genetic alterations in ATC 
 
  ATC may derive de novo or from pre-existing PTC 
or FTC. A small number of gene mutations have been identified, 
and there appears to be a progression in mutations acquired 
during dedifferentiation. Several mutations occurring in PTC 
(RAS and BRAF) are also seen in ATC, suggesting these are 
early events (Nikiforov 2004). Frequencies of RAS range from 
6% to 50% of cases. Mutation of BRAF is highly variable in 
ATC, reaching up to 25%. When ATCs with a papillary 
component were examined, BRAF mutation was observed in 
both the differentiated and undifferentiated regions (Costa et al. 
2008; Begum et al. 2004; Takano et al. 2007). 
  Late mutations include TP53, β-catenin 1 and 
PIK3CA, suggesting that one or more of these mutations 
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contribute to the extremely aggressive behavior of ATC 
(Santarpia et al. 2008; Hou et al. 2007). Mutations of TP53 
occur in more then 70% of ATCs (Salvatore et al. 2007). By 
contrast, the RET/PTC rearrangements and the PAX8/PPARg 
fusion protein detected in well-differentiated, are not observed 
ATCs (Nikiforov 2004). The β-catenin 1 is involved in WNT 
signaling and cell-adhesion. The mutation and abnormal nuclear 
localization of this protein was seen in malignancies. This 
cytoplasmic protein, encoded by the CTNNB1 gene, plays an 
important role in E-cadherin mediated cell-cell adhesion. In 
thyroid tumors, point mutations in exon 3 of CTNNB1 have 
been reported in ATC (Garcia Rostan et al. 1999). This mutation 
was detected in many ATC cases, from 50% to 60% (with 
nuclear localization in half with mutations), while abnormalities 
were detected also in poorly differentiated, in ~30% of cases 
(Garcia Rostan et al. 2001; Miyake et al. 2001). PIK3CA was 
mutated in 15-39% of ATC cases and copy gains occur in 38-
61%. AKT1 was activated in most ATC cases (85-93%) (Hou et 
al. 2007; Liu et al. 2008; Santarpia et al. 2008), PTEN, 
(phosphatase and tensin homology encoding chromosome 10), 
negatively regulates the PI3K pathway and was found mutated 
in ~30% of ATC cases (Santarpia et al. 2008) (Table 1). 
 
 
Genetic alterations in MTC  
 
  As previously mentioned, MTC can occur either 
sporadically or in the context of autosomal dominant MEN 2 
syndromes (MEN 2A, MEN 2B and FMTC) (Manié et al. 
2001). MEN 2 are caused by germ line point mutations that 
convert RET into a dominant oncogene. In all MEN2A cases, 
mutations target extracellular cysteine residues in RET. In more 
than 80% of the cases, MEN 2B is caused by the Met 918 Thr 
intracellular substitution in the P+1 loop of the kinase. FMTC 
(Familial Medullary Thyroid Carcinoma) is caused by mutations 
in the RET extracellular or kinase domains. Roughly 40% of 
sporadic MTC cases harbor similar point mutations in RET. 
  In the last years our laboratory has been launched a 
program to develop RET-directed targeted therapy for thyroid 
cancer. Thus, we generated roughly 50 monoclonal antibodies 
(mAbs) against the extracellular domain of RET and tested their 
therapeutic potential in MTC cell lines (attached manuscript III 
in preparation). 
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1.2 The transcription factor Twist1 
 
1.2.1 Structure of Twist1 
 
  Little is known about the molecular events that lead 
from the highly curable differentiated tumors to the very 
aggressive ATC. Through, a cDNA microarray analysis on 
different thyroid tumors we have isolated Twist1 transcription 
factor as a gene upregulated in ATC (Salvatore et al. 2007). 
  Human Twist1 gene is mapped to 7q21.2 and 
contains two exons and one intron (Wang et al. 1997). The first 
exon contains an ATG site followed by an open reading frame 
encoding 202 amino-acid residues. The open reading frame is 
followed by a 45-bp untranslated portion in exon 1, a 536-bp 
intron and a second untranslated exon with two potential 
polyadenylation sites that are 65 and 415 bp from the 5′ end of 
exon 2. The molecular mass calculated from the amino-acid 
sequence of human Twist1 is approximately 21 kDa, with a 
theoretical isoelectric point of ~9.6. The protein contains 
relatively more polar amino-acid residues in the region close to 
the NH2-terminus and more non-polar residues at the COOH-
terminus where the bHLH domain is located.  
  The Twist1 gene belongs to the family of basic 
helix-loop-helix (bHLH) transcription factors (Thisse et al. 
1987). bHLH proteins are structurally and functionally 
characterized by a conserved domain containing a stretch of 
basic amino-acids adjacent to two amphipathic ɑ-helices 
separated by an interhelical loop. The ɑ-helices mediate 
dimerization with a second bHLH factor, leading to the 
formation of a bipartite DNA-binding domain that specifically 
binds to hexanucleotide sequences (CANNTG), known as E-
boxes (Figure 1). The E-boxes are found in the regulatory 
elements of many lineage-specific genes. Consistently, bHLH 
are transcription factors acting in various differentiation 
processes, and play key roles in different developmental events 
like neurogenesis and myogenesis. 
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Figure 1. Structure and function of human-Twist1. a) The gene 
encoding human-Twist1 comprises two exons separated by a 
unique intron. b) The human-Twist1 protein is 202 amino acids 
with a basic helix-loop-helix (bHLH) domain. c) Interaction of 
Twist1 with DNA acting as dimers. (modified from 
Bonaventure and El Ghouzzi 2003). 
 
 
  The bHLH domains of Twist1 show a very high 
degree of conservation among a broad range of species, 
including human, mouse, frog, Drosophila, leech and 
Caenorhabditis elegans. The C-terminal part of the proteins 
comprises the WR motif also called “Twist box” (Spring et al. 
2000; Bialek et al. 2004). The WR motif is located between 20 
and 55 amino acids COOH terminal to the bHLH region, is 
highly conserved among vertebrates; the amino-acid sequences 
in this domain show 100% homology among human, mouse and 
Xenopus Twist1. The function of this WR region is unclear, it is 
postulated to be required for Twist1 protein folding and activity 
(Gripp et al. 2000).  
  Twist1 functions as a transcription factor in the cell 
nucleus. There are two nuclear localization signal (NLS) 
sequences, 37RKRR40 and 73KRGKK77, in the human Twist1 
protein. Furthermore, the N-terminus of Twist1 can interact with 
p300, cAMP-response element binding protein (CREB), CREB-
binding protein (CBP) and p300/CBP associated factor (PCAF), 
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resulting in inhibition of the acetyl transferase activities of these 
histone remodeling enzymes (Hamamori et al. 1999). Since 
histone acetylation is usually coupled with transcriptional 
activation, the inhibition of p300, CBP and PCAF activities by 
Twist1 should repress gene expressions mediated by 
transcription factors that recruit these histone acetyltransferases.  
  The C-terminus of Twist1 interacts with the DNA-
binding domain of Runx2 to repress Runx2 function (Bialek et 
al. 2004). Runx2 is a necessary transcription factor for 
osteoblast differentiation. These findings suggest that Twist1 
not only serves as a transcription factor to directly regulate its 
target genes, but also regulates other transcription 
factor/coregulator-mediated gene expression through interaction 
with other transcriptional regulators (Figure 2). 
  In addition, Twist1 protein directly interact with 
several other transcription factors, including MyoD, MEF2, 
RUNX1, PGC1-α, p53 and NF-κB and inhibit their activities 
(Sosic et al. 2003; Bialek et al. 2004; Sharabi et al. 2008; Shiota 
et al. 2008; Pan et al. 2009). 
 
 
 
 
Figure 2. Molecular structure of the human Twist1 protein. The 
number of amino-acid residues for each structural domain is 
indicated. The regions that interact with other proteins are also 
indicated by solid lines. NLS1 and NLS2, nuclear localization 
signal sequences 1 and 2; bHLH, basic helix-loop-helix domain; 
WR, the tryptophan and arginine motif; CBP, cAMP-response 
element binding protein (CREB)-binding protein; PCAF, p300/ 
CBP-associated factor, Runx2, Runt-related transcription factor. 
. 
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  Two Twist genes exist in vertebrates, Twist1 (Twist) 
and Twist2 (formerly known as Dermo-1). The human Twist2 
protein contains 160 amino-acid residues and it shares 68% 
homology with human Twist1. The amino-acid sequences of 
their bHLH and Twist box domains are almost identical, which 
provides a structural base for their partially redundant biological 
functions. Indeed Twist proteins display more than 90% identity 
in the bHLH and carboxy-terminal domains. The N-terminal of 
Twist1 and Twist2 are more divergent, and Twist2 lacks a 
glycine-rich region that is present in Twist1 (Li et al. 1995) 
(Figure 3).  
 
 
 
 
 
Figure 3. Functional domains of human Twist1 and Twist 2 
proteins. The glycine-rich region is specific of Twist 1 (modified 
from Puisieux et al. 2006). 
 
 
1.2.2 The expression of Twist1 in normal tissues 
 
  Twist1 expression was originally restricted to 
mesodermal-derived tissues, including: placenta, heart and 
skeletal muscles, presumably in precursor cells (Wang et al. 
2004). While, Twist2 was additionally found to be expressed in 
granulocyte-macrophage progenitors, preventing their 
proliferation and differentiation into macrophages, neutrophils 
and basophils (Sharabi et al. 2008). 
  During Drosophila embryogenesis, Twist1 accumulates 
at early stages (from the beginning of cellular blastoderm to 
germ band extension) in all cells of the presumptive mesodermal 
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layer, but its expression decreases to relatively low levels in the 
mesodermal layer cells during later stages. This expression 
pattern is consistent with the critical roles of this zygotic gene in 
early embryogenesis.  
  During mouse embryogenesis, Twist1 transcripts are 
first seen at embryonic day 7.5 (E7.5) in the anterior lateral 
mesoderm underlying the head folds (Fuchtbauer et al. 1995), in 
the primitive streak epiblast, and in scattered cells in the 
amniotic cavity (Stoetzel et al. 1995). Then, Twist1 is 
predominantly and sequentially expressed in the somites, the 
neural crest derived head mesenchyme, the first aortic arches, 
the lateral mesoderm, the second, third and fourth branchial 
arches, the anterior limb buds, and finally, the posterior limb 
buds (Wolf et al. 1991; Fuchtbauer 1995; Gitelman 1997). A 
general tendency is that Twist1 expression in the mouse embryo 
occurs first along a dorsoventral gradient pattern until the 
headfold stage, and then moves along the rostro-caudal axis of 
the embryos as mesoderm cell layer- and neural crest cell-
derived tissues develop.  
  After birth, Twist1 is expressed in the adult stem cells 
of the mesenchyme (Figeac et al. 2007; Zhao and Hoffman 
2004). Twist1 mRNA has also been detected in primary 
osteoblastic cells derived from newborn mouse calvariae 
(Murray et al. 1992) and in mouse brown and white adipocytes 
(Pan et al. 2009; Pettersson et al. 2011). 
  While the expression patterns of Twist1 during 
embryonic development of Drosophila and mouse have been 
well studied, information regarding the expression profile of 
Twist1 during human embryogenesis is lacking. Twist1 mRNA 
expression pattern was examined in various adult human tissues, 
as well as several cell lines originated from different normal 
human tissues (Wang et al. 1997). Among the human tissues 
analyzed, the strongest signals for Twist1 mRNA were observed 
in the placenta, a tissue containing a large fetal portion and a 
small maternal portion. In particular, strong Twist1 signals were 
seen in the fetal portion of the placenta developed from the 
chorionic sac, which is mostly derived from the mesoderm. 
Intermediate strength signals were seen in the adult heart and 
skeletal muscle, which are also mostly derived from the 
mesoderm. Weak signals were found in the kidney and 
pancreas, while no signals were observed in the ectoderm- 
derived cells in the brain and endoderm-derived cells in the lung 
and liver. Additionally, Twist1 expression is also observed in 
human white adipocytes (Pettersson et al. 2011). Twist1 
expression was not observed in human epithelial cells, although 
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its mRNA was detected in both fetal and adult human skin 
fibroblasts (Wang et al. 1997). 
 
 
1.2.3 Twist1 protein stability 
 
  Regulation of protein stability is an important way to 
control Twist1 function. Recently, it was reported that Twist1 
protein stability is largely regulated by mitogen-activated 
protein kinase (MAPK)-mediated phosphorylation on S68. The 
S68 in Twist1 can be phosphorylated by p38, JNK and ERK1/2 
MAPKs, and this phosphorylation prevents Twist1 protein from 
ubiquitination-mediated degradation (Hong et al. 2011). 
Accordingly, activation of MAPKs by an active RAS protein or 
TGFβ treatment significantly increases S68 phosphorylation and 
Twist1 protein levels without altering Twist1 mRNA 
expression, while blocking of MAPK activities by either 
specific inhibitors or dominant negative inhibitory mutants 
effectively reduces both S68 phosphorylation and Twist1 
protein levels (Hong et al. 2011).  
 
 
1.2.4 Physiological functions of Twist1 protein 
 
  Twist1, identified originally in Drosophila as a 
zygotic developmental gene, is considered crucial for the 
establishment of the ventral furrow, a prerequisite for the 
development of all mesoderm-derived internal organs (Thisse et 
al. 1987). 
  In mice Twist1 -/- have normal gastrulation but die at 
E10.5-11 displaying severe defects in closure of the cephalic 
neural tube, deficient cranial mesoderm, malformed branchial 
arches and facial primordium and retarded limb bud 
development (El Ghouzzi et al. 1997). Consistently, germ line 
mutations of the coding sequences of Twist1 gene, leading to 
haploinsufficiency, have been identified in Saethre-Chotzen 
syndrome (SCS), an human hereditary disorder transmitted as 
an autosomal dominant trait and characterized by abnormalities 
of the limbs, asymmetric head and face, and premature fusion of 
cranial sutures. Twist1-/- mice also present a significant increase 
in apoptotic cells, especially in the developing sclerotome (Chen 
and Behringer 1995). This cell death could reflect Twist1 anti-
  21 
apoptotic properties as Twist1 protein also behave as key 
regulators of the p53 oncosuppressive protein and as major 
effectors of the NF-kB survival pathway (Puiseux et al. 2006; 
Doreau et al. 2009). Heterozygosis for Twist1 null mutation 
results in a moderate phenotype including minor skull and limb 
abnormalities. Instead, Twist2 -/- do not present abnormalities of 
embryogenesis but show high levels of inflammatory cytokines 
with high perinatal mortality (Sosic et al. 2003).  
 
 
1.2.5 Overexpression of Twist1 in human cancers 
 
  In addition to its essential role in modulating 
mesenchymal tissues critical for organogenesis, Twist1 is also 
expressed in and associated with many types of aggressive 
tumors, including breast cancer (Yang et al. 2004), 
hepatocellular carcinoma (Lee et al. 2006; Yang et al. 2009), 
prostate cancer (Yuen et al. 2007), esophageal squamous cell 
carcinoma, bladder cancer (Zhang et al. 2007; Wallerand et al. 
2009) and pancreatic cancer.  
  Twist1 plays multiple roles in cancer initiation, 
progression and metastasis. Importantly, Twist1 has been 
identified as a master regulator of Epithelial-Mesenchymal 
Transition (EMT) the process in which adherent epithelial cells 
lose their epithelial characteristics and acquire mesenchymal 
properties (Ansieau et al. 2010). EMT is a critical mechanism of 
migration and invasion during development and in the case of 
cancer cells is a mechanism of increased invasion, metastasis, 
and resistance to chemotherapy. Recent studies have linked 
EMT with acquisition of stem-cell characteristics. Typical 
features of EMT are loss of expression of epithelial markers, 
mainly E-cadherin, with gain of mesenchimal markers such as 
Vimentin and sm-actin. E-cadherin, encoded by the CDH1 gene, 
is generally defined as a guardian of the epithelial phenotype 
and loss of its expression is associated with tumor invasiveness, 
metastatic dissemination and poor patient prognosis (Umbas et 
al. 1994). Repression of CDH1 gene by Twist1 is either direct 
(Vesuna et al. 2008) or mediated by SNAI1 (Smit et al. 2009).  
Together with Twist1 other transcription factors are capable, on 
its own, of inducing an EMT. These transcription factors 
include Twist2, Goosecoid, Hoxb7, Snai1 (Snail), Snai2 (Slug), 
Foxc1, Foxc2, Zeb1 and Zeb2 (Sip1). In addition, members of 
the miR-200 family of micro RNAs are down regulated during 
an EMT (Kalluri 2009). 
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  Some microRNAs may be involved in mediating 
cancer metastasis. The microRNA-10b (miR-10b) is highly 
expressed in metastatic breast cancer cells, and it positively 
regulates cell migration and invasion (Ma et al. 2007). The miR-
10b transcription is directly regulated by Twist1, and miR-10b 
in turn inhibits translation of the mRNA encoding homeobox 
D10, resulting in increased expression of the pro-metastatic 
gene RhoC. Moreover, the level of miR-10b expression in 
primary breast carcinomas is associated with clinical cancer 
progression. These findings suggest that Twist1 indirectly 
upregulates RhoC expression to increase breast cancer, cell 
invasion and metastasis. 
 
 
1.2.6 Role of Twist1 in cancer cell survival, immortalization 
and acquired chemoresistance 
 
  Oncogenic mutations usually induce p53 and/or 
retinoblastoma (Rb) expression and result in cell apoptosis or 
senescence, which is a defensive barrier against cell 
transformation and tumor progression. Thus, tumorigenesis 
needs to protect cells from apoptosis or immortalize cells from 
senescence. Interestingly, both Twist1 and Twist2 were shown 
to inhibit oncogene-induced and p53- dependent cell death 
(Ansieau et al. 2008). Further analysis revealed that Twist1 
might affect p53 indirectly through inhibition of ARF 
expression to modulate the ARF/MDM2/p53 pathway (Maestro 
et al. 1999). Twist1 promote chromosomal instability and 
consequently tumor progression. Accordingly ectopic 
expression of Twist1 in the MCF7 breast cell line induces 
chromosomal instability and frequencies of chromosomal 
amplifications are significantly higher in Twist1 -expressing 
breast carcinomas (Mironchik et al. 2005). 
  Twist1 also plays a role in the acquired resistance of 
cancer cells to chemotherapy. Twist1 upregulation is associated 
with cellular resistance to taxol and vincristine, two 
microtubule-targeting anticancer drugs in nasopharyngeal, 
bladder, ovarian, and prostate cancers (Wang et al. 2004) On the 
other hand, the chemotherapy-induced cancer cell apoptosis is 
counter-regulated by a subset of NF-κB regulated genes. Twist1 
is one of the major targets of NF- κB responsible for 
antagonizing chemotherapy-induced apoptosis, suggesting an 
important role of Twist1 in NF- κB-mediated cell survival and 
chemoresistance (Pham et al. 2007). 
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  Multiple lines of evidence have demonstrated a link 
between Twist1-induced EMT and stem-like cells. It was 
demonstrated that induction of EMT by expressing Twist1 or 
Snail in mammary epithelial cells increases stem-like cell 
population with high CD44 and low CD24 expression, while 
isolated mammary epithelial stem-like cells express endogenous 
EMT-inducing factors including Twist1, Snail, SIP1, Slug and 
FOXC2, and EMT marker genes (Mani et al. 2008). 
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2. AIMS OF THE STUDY 
 
The aim of this study was to analyze the role of Twist1 
transcription factor in thyroid cancer progression. The specific 
aims were as follow: 
 
1. Study the expression of Twist1 in normal human thyroids, 
PTC, PDC and ATC samples by quantitative RT-PCR and 
immunohistochemistry. 
2. Study the functional consequences of Twist1 knockdown 
(in endogenously overexpressing cells) and of ectopic 
expression (in negative cells) on cell growth, survival, 
migration and invasion. 
3. Identify a transcriptional profile of genes that mediates 
Twist1 biological effects in thyroid cancer cells.  
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3. MATERIALS AND METHODS 
 
3.1 Cell lines 
 
  Normal thyroid primary S11N and P5 4N cells were 
grown in RPMI (Roswell Park Memorial Institute) 
supplemented with 20% FBS (Fetal Bovine Serum), L-
glutammine and penicillin/streptomycin. Human papillary 
(TPC-1, BCPAP and NIM) and anaplastic (8505C, CAL62, 
OCUT-2) thyroid cancer cell lines were grown in DMEM 
(Dulbecco's Modified Eagle Medium), supplemented with 10% 
FBS, L-glutammine and penicillin/streptomycin. All the cells 
were SNP genotyped to ensure correct identity. The Fischer rat-
derived differentiated thyroid follicular cell line PC Cl 3 (here 
after named “PC”) and PC adoptively expressing several 
oncogenes (PC RET/PTC1, PC RET/PTC3, PC v-HRAS, PC-
BRAF-V600E, PC-TRK-T1, PC v-RAF, PC v-MOS, PC E1A 
and PC E1A-v-RAF) have been cultured as described in the 
attached manuscript II. 
 
3.2 Tissue samples 
 
  Tumors and normal thyroid tissue samples for 
immunohistochemical analysis were retrieved from the files of 
the Pathology Department of the Hospital Central de Asturias 
(Oviedo University, Asturias, Spain) and of the Hospital Clinico 
Universitario de Santiago de Compostela (Santiago de 
Compostela University, Galicia, Spain). Tumors and normal 
thyroid tissue samples for RNA extraction and Q-RT-PCR were 
retrieved from the files of the Department of Surgery, 
University of Pisa (Italy). Detailed of the histological diagnosis 
is described in the attached manuscript II.  
 
 
3.3 Immunohistochemistry 
 
  The experimental procedure is discussed in detail in the 
attached publication II. A brief description is provided here.   
Slides of tumor sections deparaffinized were incubated with 
mouse monoclonal antibody against Twist1 (sc-81417, Santa 
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Cruz Biotechnology, USA) and processed according to standard 
procedures. Cases were scored as positive when unequivocal 
brown staining was observed in the nuclei of tumor cells. 
Immunoreactivity was expressed as the percentage of positively 
stained target cells in four intensity categories [-, no staining; +, 
low/weak; ++ moderate/distinct; +++, high/ intense].  
 
 
3.4 Reverse transcription and quantitative PCR 
  
  Total RNA was isolated with the RNeasy Kit 
(Qiagen, Crawley, West Sussex, UK). The quality and 
concentration of the RNA was verified by the NanoDrop 2005 
(Thermo Scientific). One µg of total RNA from each sample 
was reverse-transcribed with the QuantiTect ® Reverse 
Transcription (Qiagen) according to manufacturer’s 
instructions. The expression level of each gene was measured 
by quantitative PCR assay, using the Universal ProbeLibray 
Set, Human (Roche). PCR reactions were performed in 
triplicate and fold changes were calculated with the formula: 2-
(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the 
amplification fluorescent thresholds of the mRNA of interest 
and the mRNA of RNA polymerase 2 used as an internal 
reference. 
 
 
3.5 Protein studies 
 
  Immunoblotting was carried out according to 
standard procedures. Anti-α-Twist1 (sc-81417) monoclonal 
antibody was from Santa Cruz Biotechnology and anti-α-
tubulin antibody was from Sigma-Aldrich. Secondary anti-
mouse and anti-rabbit antibodies coupled to horseradish 
peroxidase were from Santa Cruz Biotechnology.  
 
 
3.6 RNA silencing 
 
 The procedure to silence Twist1 is described in detail in 
the attached manuscript II.  
To silence Twist1 target genes (i.e. HS6ST2, ID4, PDZK1, 
PDZK1lP1 and TACSTD1), the TPC-1 Twist1 mp or the 
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OCUT-2 or the CAL62 cells were transfected with the specific 
siRNA (Qiagen) in 6-well plate in triplicate. For each 
transfection, 5 μl of 100 micromolar siRNA (25 nM) were 
mixed with 20 μl of HyPerfect Transfection reagent (Qiagen) 
and 300 μl of Optimem medium (Invitrogen). Following 10 
minutes of incubation, the transfection mix was delivered to 
each well and incubated at 37°C for 72 hours. 
 
 
3.7 Twist1 transfection 
 
  To generate a cell line stably expressing Twist1 we 
used TPC-1 cells in which we transfected the vector pcDNA 3-
Twist1 (described in Demontis et al. 2006). Protocol procedure 
is detailed in attached manuscript II.  
  To generate stable shTwist1-expressing cell line, 
CAL62 cells were transfected with shTwist1 and shLUC 
vectors by using the Lipofectamine Reagent (Invitrogen) 
according to the instructions of the manufacturer. Protocol 
procedure is detailed in attached manuscript II.  
 
 
3.8 Cell viability measurement 
 
  Cells were collected by trypsinization, stained for 10 
minutes with 0.4% trypan-blue (Sigma) according to 
manufacturer’s instructions, and counted in triplicate. 
 
 
3.9 Chemoinvasion Assay 
 
  Cell invasion was examined using a reconstituted 
extracellular matrix (Matrigel, BD Biosciences, San Jose, CA). 
The cell suspension (1 x 105 cells per well) was added to the 
upper chamber of trans well cell culture chambers on a 
prehydrated polycarbonate membrane filter of 8 μm pore size 
(Costar, Cambridge, MA) coated with 35 μg of Matrigel (BD 
Biosciences). The lower chamber was filled with 2.5% medium. 
After 12 hours incubation at 37°C, non migrating cells on the 
upper side of the filter were wiped-off. Invading cells were 
mounted on glass slides using mounting medium and stained 
with Hoechst (Sigma). Cell migration was quantified by 
  28 
counting the number of stained nuclei in five individual fields in 
each Transwell membrane, by fluorescence microscopy, in 
triplicate. 
 
 
3.10 Wound Healing Assay 
 
  A wound was induced on the confluent monolayer 
cells by scraping a gap using a micropipette tip. Photographs 
were taken at 10 X magnification using phase-contrast 
microscopy immediately after wound incision and 24 hours 
later. Pixel densities in the wound areas was measured using the 
Cella software (Olympus Biosystem Gmb) and expressed as 
percentage of wound closure where 100 % is the value obtained 
at 10 hours for control cells. 
 
 
3.11 Microarray Analysis 
 
  10 µg purified total RNA from 3 Twist1 TPC-1 
transfectants (Twist1 mp1, Twist1 mp2, Twist1 Cl2) and 
pcDNA mp2 control was transcribed into cDNA using 
Superscript RT (Invitrogen), in the presence of T7-oligo (dT) 24 
primer, deoxyribonucleoside triphosphates (dNTPs), and T7 
RNA polymerase promoter (Invitrogen). An in vitro 
transcription reaction was then performed to generate 
biotinylated cRNA which, after fragmentation, was used in a 
hybridization assay on Affymetrix U133 plus 2.0 GeneChip 
microarrays, according to manufacturer's protocol (GeneChip 3' 
ivt Express Kit, Affymetrix). Normalization was performed by 
global scaling and analysis of differential expression was 
performed by Microarray Suite software 5.0 (Affymetrix). The 
final results were imported into Microsoft Excel (Microsoft). 
 
 
3.12 Statistical analysis 
 
  Statistical analyses were carried out using the 
GraphPad InStat software program (version 3.06.3, San Diego, 
CA). All p values were two-sided and differences were 
significant when p < 0.05.  
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4. RESULTS 
 
 
4.1 Up-regulation of Twist1 in ATC 
 
  We evaluated Twist1 expression levels by 
immunohistochemistry in 157 human tissues including: 15 
normal thyroids (NT), 13 PTC, 88 PDC, and 41 ATC samples. 
The data are detailed in the attached manuscript II. Twist1 was 
virtually undetectable in NT, PTC, and PDC samples. In 
contrast, 49% of the ATC samples were positive for Twist1 
expression (Figure 4).  
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Figure 4. Immunohistochemical analysis of Twist1 protein 
expression in normal and malignant thyroid tissues. 
Representative histological sections from NT, classical PTC, 
follicular variant PTC, PDC, and ATC stained with a mouse 
monoclonal anti-Twist1 antibody are shown. 
 
 
  Twist1 positivity correlated with moderate/high 
proliferation rate assessed by Ki67/MIB1 immunoreactivity. 
Twist1 expression correlated with the fusocellular ATC 
phenotype and inversely correlated with the epithelioid ATC 
phenotype, suggesting that Twist1 is involved in mesenchymal 
transition of ATC cells. Accordingly, there was a trend toward a 
correlation between Twist1 upregulation and lack of β-catenin 
staining at the plasma membrane (data not shown). 
  To determine whether Twist1 up-regulation also 
occurred at the RNA level, we examined an independent set of 
ATC, PDC, PTC, and NT samples by quantitative RT-PCR. 
Twist1 mRNA was up-regulated by more than 5-fold in about 
50% of the ATC samples (data are described in detail in the 
attached manuscript II). NT, PTC, and PDC samples express 
lower Twist1 levels compared with ATC (Figure 5). 
 
 
 
 
Figure 5. Quantitative RT-PCR of Twist1 mRNA in NT, PDC 
and ATC snap-frozen tissue samples. The level of Twist1 
expression in each sample was measured by comparing its 
fluorescence threshold with the average fluorescence threshold 
of the NT samples. 
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  Furthermore, we measured Twist2 expression by 
quantitative RT-PCR in thyroid tissue samples. Twist2 was 
overexpressed in some cases, but at a lower extent with respect 
to Twist1. No PTC sample up-regulate Twist2 (data are shown 
in the supplemental information of the attached manuscript II). 
 
 
4.2 Up-regulation of Twist1 in thyroid cancer cell lines 
 
  We analyzed Twist1 expression in cultured human 
thyroid cells. To this aim, we used primary cultures of normal 
follicular cells (P5 4N and S11N) and a panel of PTC (TPC-1, 
NIM, BCPAP) and ATC (ACT-1, OCUT-2, 8505C, SW1736, 
CAL62) cell lines. Western blot analysis showed up-regulation 
of a band at approximately 26 kDa, which corresponded to the 
Twist1 protein only in the ATC cell lines OCUT-2, 8505C, and 
CAL62 (Figure 6). Twist1 expression was lower in the other 
ATC cells and in all the PTC cell lines analyzed, whereas it was 
undetectable in normal cells. 
 
 
 
 
 
Figure 6. NT follicular cells (P5 4N and S11N), PTC (TPC-1, 
NIM, and BCPAP), and ATC (ACT- 1, OCUT-2, 8505C, 
SW1736, and CAL62) cell lines were analyzed by immunoblot 
using a mouse monoclonal anti-Twist1 antibody. Anti α-tubulin 
monoclonal antibody was used as a control for equal protein 
loading. 
 
 
4.3 Knockdown of Twist1 induces apoptosis of ATC cells  
 
  We evaluated the effects of Twist1 ablation in ATC 
cells by RNA interference. We initially tested, by Western blot 
  32 
in CAL62 cells, the efficiency of Twist1 ablation using three 
different siRNA (# 3, 5, and 7). Twist1 siRNA 3 (hereafter 
named Twist1 siRNA) reduced Twist1 protein levels of about 
60% and therefore was selected for further experiments (data 
are shown in the supplemental information of the attached 
manuscript II). Then, we knocked down Twist1 by transient 
siRNA Twist1 transfection in CAL62, 8505C, and OCUT-2 
cells. The Twist1 siRNA silenced the Twist1 protein starting at 
24 h after transfection, and the effect lasted up to 72 h, whereas 
a scrambled siRNA control had no effect (the data are shown in 
attached manuscript II). At 48 and 72 h, siRNA Twist1 induced 
apoptosis of CAL62 and 8505C cells as measured by 
immunoblot with an antibody for the cleaved products of 
caspase 3 (the data are described in attached manuscript II). 
  Accordingly, the percentages of trypan blue excluding 
(viable) cells, of CAL62 transfected with Twist1 siRNA 48 and 
72 hours after transfection, were of 69 and 32%, respectively, 
with respect to scrambled control, confirming that Twist1 
depletion reduced thyroid cancer cell viability (Figure 7). 
 
 
 
 
 
 
Figure 7. CAL62 cell line was transfected with Twist1 siRNA 
or scrambled siRNA; after 48 and 72 h, cells were collected by 
trypsinization and counted in triplicate.  
 
  We evaluated the migration by Wound-Healing assay 
and invasion (the data are detailed in attached manuscript II) 
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ability of Twist1 siRNA-transfected cells compared with 
scrambled siRNA-transfected cells. 8505C and OCUT-2 cells 
transfected with the scrambled control efficiently migrated into 
the wound; in contrast, cells transfected with Twist1 siRNA had 
a greatly reduced migrating ability (Figure 8). 
 
 
 
 
Figure 8. Cells were transfected with Twist1 siRNA or 
scrambled siRNA; a scraped wound was introduced and cell 
migration into the wound was monitored at 24 hours. Wound 
closure was measured by calculating pixel densities in the 
wound area and expressed as percentage of wound closure of 
triplicate areas ± SD.  
 
 
4.4 Effects of stable silencing of Twist1 in CAL62 cells  
 
  We stably transfected CAL62 cells with an shTwist1 
plasmid or with shLUC control. After antibiotic selection, cells 
were screened by Western blot for Twist1 expression. A mass 
population (mp) (shTwist1 mp) with a Twist1 knockdown of 
approximately 50% was used for further study. Consistent with 
data obtained upon transient Twist1 silencing, shTwist1 mp 
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cells showed decreased migration and invasion ability and a 
decreased viability compared to control (the data are detailed in 
attached manuscript II). 
 
 
4.5 Ectopic Twist1 promotes cell migration and invasion of 
PTC cells 
 
  PTC cells, TPC-1, which have low endogenous levels 
of Twist1, were transfected with a Twist1-expressing plasmid 
(pcDNA-Twist1) or with the empty vector (pcDNA). Mass 
populations and cell clones were selected. Twist1 expression 
was increased (4- to 13- fold) in all the cell lines transfected 
with Twist1 compared with the controls (the data are shown in 
attached manuscript). Growth rate was similar in Twist1- and 
vector-transfected control cell lines. 
  Therefore, we studied cell migration using the wound 
closure assay. As shown in Figure 9, the migration rate was 
higher in Twist1-transfected cells than in control cells. 
 
 
 
 
Figure 9. Cells were transfected with Twist1 siRNA or 
scrambled siRNA; a scraped wound was introduced and cell 
migration into the wound was monitored at 24 hours. Wound 
closure was measured by calculating pixel densities in the 
wound area and expressed as percentage of wound closure of 
triplicate areas ± SD.  
 
  We next evaluated Twist1- transfected and control cells 
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for their ability to invade Matrigel. Twist1 transfectants had a 
greater ability to invade Matrigel (data are shown and detailed 
in attached manuscript II).  
 
 
4.6 Ectopic Twist1 protects PTC cells from apoptosis 
 
  We treated TPC-1 cells transfected with Twist1 or 
control vector with different concentrations of Cisplatin (200, 
1000, and 2000 nM) and counted cells 24 hours upon treatment. 
As shown in Figure 10, cell viability was higher in Twist1-
transfected than in control cells upon treatment with the highest 
dose of Cisplatin. 
 
 
 
 
Figure 10. The indicated cells were treated with increasing 
doses of Cisplatin and counted 24 h after treatment. Data are 
shown as percentage of inhibition of cell viability.  
 
  Moreover, the amount of caspase 3 cleaved products 
was lower in Twist1-transfected than in control cells (data are 
shown and detailed in attached manuscript II). Thus, Twist1 
overexpression protected thyroid cancer cells from cell death 
induced by Cisplatin. This data suggests that Twist1 may be 
exploited as a molecular marker of the response of thyroid 
cancer to chemotherapy. 
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4.7. Identification of Twist1 target genes 
 
  To determine the molecular mechanisms by which 
Twist1 regulates anaplastic thyroid cancer phenotype, we 
analyzed gene expression profiles in TPC-1 Twist1 transfected 
cells. Total RNA extracted from three TPC Twist1 stable 
transfectants (Twist1 mp1, Twist1 mp2 and Twist1 Cl2) was 
used to examine their gene expression profile in comparison to 
vector control transfected cells. The screening was conducted 
in collaboration with Aarhus Biotechnology (Aarhus, 
Denmark) using the human Genome U133 Plus 2.0 Array 
GeneChips (Affymetrix) containing > 47.000 gene transcripts. 
We analyzed only the genes that were changed in all the three 
Twist1 transfectant compared to vector control cells. Genes 
were analyzed only if the signal intensity was ≥ 50. We found 
37 genes upregulated more than ∼ 3 fold and 42 downregulated 
more than ∼ 5 fold in TPC Twist1 transfectant compared to 
vector control cells. In Table 2 and 3 are shown, respectively, 
the list of the genes upregulated and downregulated.  
 
 
Table 2: List of genes upregulated more than ∼3 fold in Twist1 
overexpressing TPC cells (Twist1 mp1, Twist1 mp2, Twist1 
Cl2) versus vector (pcDNA mp) transfected cells (n=37). 
 
 
Gene Name Gene Symbol 
Fold Change 
(average of fold change in Twist1 
mp1, Twist1 mp2, Twist1 Cl2 
versus pcDNA mp) SD 
heparan sulfate 6-O-
sulfotransferase 2* HS6ST2 10.28 0.35 
CD24 molecule* CD24 8.66 1.82 
collagen type I alpha 1 COL1A1 7.22 1.41 
GDNF family receptor alpha 1 GFRA1 6.92 0.61 
keratin 7 KRT7 5.57 0.83 
vang-like 2 (van gogh. 
Drosophila) VANGL2 5.48 0.31 
matrix-remodelling associated 8 MXRA8 5.42 0.58 
plakophilin 2* PKP2 5.34 0.87 
coagulation factor II (thrombin) 
receptor-like 1 F2RL1 5.31 0.95 
leprecan-like 1 LEPREL1 4.99 0.47 
thyroid hormone receptor. beta 
(erythroblastic leukemia viral (v-
erb-a) oncogene homolog 2. avian) THRB 4.88 0.87 
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zinc finger. BED-type containing 
2 ZBED2 4.60 0.66 
ADAM metallopeptidase with 
thrombospondin type 1 motif. 5 
(aggrecanase-2)* ADAMTS5 4.37 0.85 
inhibitor of DNA binding 4. 
dominant negative helix-loop-
helix protein* ID4 4.34 0.26 
ras homolog gene family. member 
B* RHOB 4.14 0.61 
PDZ domain containing 1* PDZK1 3.99 0.55 
netrin 4 NTN4 3.98 0.75 
papilin. proteoglycan-like sulfated 
glycoprotein* PAPLN 3.95 0.70 
cytochrome P450. family 24. 
subfamily A. polypeptide 1 CYP24A1 3.90 0.97 
filaggrin FLG 3.73 0.69 
AKIP1 
A kinase 
(PRKA) 
interacting 
protein 1 
(AKIP1) 
3.64 0.52 
coiled-coil domain containing 80 CCDC80 3.59 0.86 
transforming growth factor. beta-
induced TGFBI 3.50 0.20 
Suppression of tumorigenicity 7 
like ST7L 3.45 0.87 
prostaglandin I2 (prostacyclin) 
synthase PTGIS 3.43 0.78 
transgelin TAGLN 3.41 1.01 
mal. T-cell differentiation protein 
2 MAL2 3.38 0.52 
EGF-like repeats and discoidin I-
like domains 3 EDIL3 3.29 0.64 
tumor-associated calcium signal 
transducer 1* TACSTD1 3.24 0.95 
death-associated protein kinase 1* DAPK1 3.21 0.62 
LIM and cysteine-rich domains 1 LMCD1 3.20 0.46 
WAS protein family. member 3 WASF3 3.12 0.59 
microphthalmia-associated 
transcription factor* MITF 2.95 0.85 
phospholipase C, beta 4 PLCB4 2.93 0.79 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 1* ADAMTS1 2.93 0.78 
 
chromosome 10 open reading 
frame 65 C10orf65 2.92 0.61 
PDZK1 interacting protein 1* PDZK1IP1 2.90 0.57 
 
• * Genes that were further studied.  
 
 
 
  38 
 
Table 3: List of genes downregulated more than 5 fold in Twist1 
overexpressing TPC cells  (Twist1 mp1, Twist1 mp2, Twist1 Cl2) 
versus vector (pcDNA mp) transfected cells (n=42). 
   
Gene Name Gene Symbol 
Fold Change 
(average of fold change in 
Twist1 mp1,Twist1 mp2, Twist1 
Cl2 versus pcDNA mp) SD 
peroxisomal biogenesis 
factor 5-like PEX5L -32.00 3.25 
NADPH oxidase. EF-hand 
calcium binding domain 5 NOX5 -25.62 2.82 
hydroxysteroid (11-beta) 
dehydrogenase 1 HSD11B1 -24.56 2.21 
chromosome 10 open 
reading frame 116 C10orf116 -24.37 2.72 
protocadherin 7* PCDH7 -23.27 2.57 
interleukin 13 receptor. alpha 
2 IL13RA2 -23.06 2.65 
granzyme A (granzyme 1. 
cytotoxic T-lymphocyte-
associated serine esterase 3) GZMA -19.47 1.37 
Rho GTPase activating 
protein 9* ARHGAP9 -15.03 1.86 
hematopoietic cell-specific 
Lyn substrate 1 HCLS1 -12.84 2.03 
G protein-coupled receptor 
65 GPR65 -11.25 1.44 
FAT tumor suppressor 
homolog 3 (Drosophila) FAT3 -9.70 2.02 
solute carrier family 22 
(organic cation transporter). 
member 18 antisense SLC22A18AS -9.63 1.64 
BCL2-related protein A1 BCL2A1 -9.27 1.66 
linker for activation of T 
cells family. member 2 LAT2 -8.22 1.40 
serpin peptidase inhibitor. 
clade D (heparin cofactor). 
member 1 SERPIND1 -8.15 1.61 
heat shock 70kDa protein 1A HSPA1A -7.85 1.47 
myeloma overexpressed 
gene (in a subset of t(11;14) 
positive multiple myelomas) MYEOV -7.78 0.68 
gap junction protein. beta 2. 
26kDa GJB2 -7.68 1.70 
protease. serine. 3 
(mesotrypsin) PRSS3 -7.64 1.26 
growth hormone receptor GHR -7.38 1.01 
interleukin 1. alpha IL1A -7.08 1.11 
synaptotagmin-like 3 SYTL3 -6.86 1.47 
vanin 1 VNN1 -6.59 0.92 
SLAIN motif family. 
member 1 SLAIN1 -6.30 1.05 
keratin 15* KRT15 -6.15 1.14 
baculoviral IAP repeat-
containing 3 BIRC3 -6.13 1.27 
podoplanin PDPN -6.12 1.31 
tissue factor pathway 
inhibitor 2 TFPI2 -6.02 1.39 
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chemokine (C-X-C motif) 
ligand 3 CXCL3 -5.69 0.68 
interleukin 7 IL7 -5.62 0.97 
hypothetical protein 
LOC339400 LOC339400 -5.57 1.05 
phosphatidylinositol 3.4.5-
trisphosphate-dependent 
RAC exchanger 1* PREX1 -5.47 1.12 
epithelial membrane protein 
1 EMP1 -5.47 1.70 
sorbin and SH3 domain 
containing 1 SORBS1 -5.36 1.27 
neurotrimin HNT -5.31 1.01 
absent in melanoma 1 AIM1 -5.18 1.08 
signal-regulatory protein 
beta 1 SIRPB1 -5.17 1.25 
thrombomodulin THBD -5.13 0.38 
Rho GDP dissociation 
inhibitor (GDI) beta* ARHGDIB -4,98 1,15 
sorbin and SH3 domain 
containing 1 SORBS1 -4.8 1.19 
G0/G1switch 2 GOS2 -4.8 1.18 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 7 SLC7A7 -4.80 0.85 
carbohydrate (keratan sulfate 
Gal-6) sulfotransferase 1 CHST1 -4.76 1.28 
metastasis suppressor 1* MTSS1 -4.70 0.60 
 
 
* Genes that were further studied. 
 
 
  We used the Ingenuity pathways Analysis (Ingenuity 
Systems, www.ingenuity.com) to classify the genes in 
pathway. Molecules from the dataset were associated with 
Ingenuity’s Knowledge Base. Signal pathways that were 
mostly changed in Twist1 transfected cells were: RhoA 
Signaling, Death Receptor Signaling, Wnt/β-catenin Signaling, 
Hepatic Stellate Cell Activation, Apoptosis Signaling.  
  Among these top changed genes we further selected 13 
genes upregulated and 7 genes downregulated for further 
validation. The genes upregulated further studied were: 
ADAMTS1 (ADAM metallopeptidase with thrombospondin 
type 1 motif, 1), ADAMTS5 (ADAM metallopeptidase with 
thrombospondin type 1 motif 5), CD24 (CD24 molecule), 
DAPK1 (death-associated protein kinase 1), HS6ST2 (heparan 
sulfate 6-O-sulfotransferase 2), ID4 (inhibitor of DNA binding 
4 dominant negative helix-loop-helix protein), PAPLN 
(papilin, proteoglycan-like sulfated glycoprotein), PDZK1 
(PDZ domain containing 1), PDZK1IP1 (PDZK1 interacting 
protein 1), PKP2 (plakophilin 2), RHOB (ras homolog gene 
family. member B), TACTSD1 (tumor-associated calcium 
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signal transducer and WASF3 (WAS protein family. member 3 
microphthalmia-associated transcription factor). The genes 
downregulated further studied were: ARHGDIB (Rho GDP 
dissociation inhibitor (GDI) beta), ARGHPA9 (Rho GTPase 
activating protein 9), GPR65 (G protein-coupled receptor 65), 
KRT15 (keratin 15), PCDH7 (protocadherin 7), MTSS1 
(metastasis suppressor 1) and PREX1 (phosphatidylinositol 
3.4.5-trisphosphate-dependent RAC exchanger 1) cells. We 
chose these genes on the basis of their fold change and on what 
is known of their role in the literature.  
  Initially, we confirmed the microarray data by 
performing quantitative RT-PCR in the cell lines used for the 
screening: TPC Twist1 mp1, Twist1 mp2 and Twist1 Cl2 in 
comparison to vector control transfected cells, furthermore we 
used also Twist1 Cl10 (see attached manuscript II). As shown 
in the Figure 11, all the 13 genes upregulated were confirmed 
(with some degree of variability among the clones) in all cells 
transfected with Twist1 compared to control (p < 0.01). 
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Figure 11. Quantitative RT-PCR of the indicated genes in TPC 
Twist1 transfectant cells in comparison to vector control. 
Asterisks indicate: p < 0.01 (**) and p < 0.001 (***). 
 
 
Similar results were obtained for the genes downregulated 
(Figure 12).  
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Figure 12. Quantitative RT-PCR of the indicated genes in TPC 
Twist1 transfectant cells in comparison to vector control. 
Asterisks indicate: p < 0.01 (**) and p < 0.001 (***). 
 
 
4.8 Expression of Twist1 target genes in CAL62 shTwist1 
transfected cells 
 
  To further confirm that Twist1 transcriptionally 
regulates this set of genes, we studied whether the suppression 
of Twist1 affect the expression levels of the 20 genes. Thus, we 
performed quantitative RT-PCR for the 13 upregulated genes 
and 7 downregulated in the ATC, CAL62 cell line stably 
transfected with an shTwist1 plasmid. As shown in Figure 13, 
transfection of CAL62 cell line with a Twist1 shRNA 
promoted a severe downregulation of ADAMTS1, CD24, 
HS6ST2, ID4, PAPLN, PDZK1, PDZK1IP1, PKP2, RHOB, 
TACTSD1 and WASF3 mRNA with respect to the control cells 
transfected with an irrelevant shRNA (shLUC) (p < 0.01).  
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Figure 13. Quantitative RT-PCR of the indicated genes in 
CAL62 shTwist1 transfectant cells in comparison to vector 
control. Asterisks indicate: p < 0.01 (**) and p < 0.001 (***). 
 
 
  On the contrary, Twist1 downregulated genes i.e. 
ARHGDIB, GPR65, KRT15, PCDH7 and MTSS1 were 
upregulated upon Twist1 silencing (Figure 14). 
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Figure 14. Quantitative RT-PCR of the indicated genes in 
CAL62 shTwist1 transfectant cells in comparison to vector 
control. Asterisks indicate: p < 0.01 (**) and p < 0.001 (***). 
 
 
4.9 Silencing of Twist1 target genes in cells ectopically 
expressing Twist1 (TPC Twist1 mp 1) 
 
  To further study the functional significance of our 
findings we transfected siRNA specific for the genes HS6ST2, 
ID4, PDZK1, PDZK1IP1 and TACSTD1 in the TPC cells 
overexpressing Twist1 (TPC Twist1 mp1). We choose to start 
from these genes because they were significantly changed in the 
quantitative RT-PCR. 
  TPC Twist1 mp cells were transiently transfected 
with siRNA for HS6ST2, ID4, PDZK1, PDZK1IP1 and 
TACSTD1 or a scrambled siRNA and examined 72 hours post-
transfection. We initially verified by quantitative RT-PCR that 
the specific siRNA silenced the corresponding gene. As shown 
in the Figure 15, siRNA for HS6ST2, ID4, PDZK1, PDZK1IP1 
and TACSTD1 efficiently downregulated the specific gene in 
TPC Twist1 mp transfected cells (p < 0.001). 
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Figure 15. Cells were transiently transfected with the indicated 
siRNA. After 72 hours RNA was extracted and mRNA 
expression levels were measured by quantitative RT-PCR. 
Results are reported as fold change in comparison to the 
scrambled control. Asterisks indicate: p < 0.001 (***). 
 
 
  Then, we measured cell viability using trypan blue 
assay. TPC Twist1 mp1 cells were transfected in transient with 
siRNA for HS6ST2, ID4, PDZK1, PDZK1IP1 and TACSTD1, 
72 hours after transfection cells were stained with trypan blue 
and counted. As shown in Figure 16, transient silencing of 
HS6ST2, ID4, PDZK1, PDZK1IP1 and TACSTD1 impaired 
viability of TPC Twist1 mp cells (p < 0.001). 
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Figure 16. TPC- Twist1 mp cell line was transfected with 
HS6ST2, ID4, PDZK1, PDZK1IP1 and TACSTD1 siRNA or 
scrambled siRNA; after 72 hours, cells were collected by 
trypsinization, stained for 10 min with trypan-blue and counted 
in triplicate. The percentage of trypan blue excluding cells 
compared to cells transfected with siRNA scrambled is reported 
± SD. Asterisks indicate p < 0.001 (***). 
 
 
4.10 Silencing of HS6ST2, ID4, PDZK1, PDZK1IP1 and 
TACSTD1 reduced cell viability in OCUT-2 cells 
 
  To confirm the data obtained we also used the ATC cell 
line OCUT-2 that endogenously express high levels of Twist1 
(shown in the manuscript attached II). OCUT-2 cells were 
transiently transfected with siRNA specific for HS6ST2, ID4, 
PDZK1, PDZK1IP1 and TACSTD1 or scrambled siRNA and 
examined 72 hours post- transfection. As shown in the Figure 
17, silencing of HS6ST2, ID4, PDZK1, PDZK1IP1 and 
TACSTD1 was effective with a reduction of mRNA levels from 
2 to more than 10 fold.  
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Figure 17. Cells were transiently transfected with the indicated 
siRNA. After 72 hours RNA was extracted and mRNA 
expression levels were measured by quantitative RT-PCR. 
Results are reported as fold change in comparison to the 
scrambled control. Asterisks indicate: p < 0.001 (***). 
 
 
  Then, we measured cell viability using trypan blue 
assay. OCUT-2 cells were transfected in transient with siRNA 
for HS6ST2, ID4, PDZK1, PDZK1IP1 and TACSTD1; 72 
hours after transfection cells were stained with trypan blue and 
counted. As shown in Figure 18, cells viability was significantly 
impaired in cells transfected with siRNA for HS6ST2, ID4, 
PDZK1, PDZK1IP1 and TACSTD1 compared to control (p < 
0.001).  
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Figure 18: OCUT-2 cell line was transfected with HS6ST2, ID4, 
PDZK1, PDZK1IP1 and TACSTD1 siRNA or scrambled siRNA; 
after 72 hours, cells were collected by trypsinization, stained for 10 
min with trypan-blue and counted in triplicate. The percentage of 
trypan blue excluding cells compared to cells transfected with siRNA 
scrambled is reported ± SD. Asterisks indicate: p < 0.01 (**) and p < 
0.001 (***). 
 
 
4.11 Silencing of genes HS6ST2, PDZK1, PDZK1IP1 and 
TACSTD1 reduced cell viabilty in CAL62 cells 
 
  Finally, we have used another ATC cell line CAL62 
in which we showed that Twist1 depletion affected several hallmarks 
of malignancy, including anchorage independent proliferation, 
survival, and invasion (see attached manuscript II). As shown in 
Figure 19, HS6ST2, PDZK1, PDZK1IP1 and TACSTD1 mRNA were 
significantly downregulated upon respective siRNA transfection in 
CAL62 cells (p < 0.001). 
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Figure 19. Cells were transiently transfected with the indicated 
siRNA. After 72 hours RNA was extracted and mRNA 
expression levels were measured by quantitative RT-PCR. 
Results are reported as fold change in comparison to the 
scrambled control. Asterisks indicate: p < 0.001 (***). 
 
  Furthermore, in agreement with the data obtained in 
the other Twist1 overexpressing cells (TPC Twist1 mp and 
OCUT-2), cells viability in CAL62 transfected with siRNA for 
HS6ST2, PDZK1, PDZK1IP1 and TACSTD1 was greatly 
impaired compared to cells transfected with siRNA scrambled 
(Figure 20).  
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Figure 20. CAL62 cell line was transfected with HS6ST2, 
PDZK1, PDZK1IP1 and TACSTD1 siRNA or scrambled 
siRNA; after 72 hours, cells were collected by trypsinization, 
stained for 10 min with trypan-blue and counted in triplicate. 
The percentage of trypan blue excluding cells compared to cells 
transfected with siRNA scrambled is reported ± SD. Asterisks 
indicate: p < 0.01 (**) and p < 0.001 (***). 
 
 
  Further experiments on cell migration (by wound closure 
assay) and cell invasion (by matrigel assay) upon knockdown of 
HS6ST2, ID4, PDZK1, PDZK1IP1 and TACSTD1, in TPC 
Twist1 mp1, OCUT-2 and CAL62 cells are ongoing in our 
laboratory. 
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5. DISCUSSION 
 
  Thyroid cancer includes tumor types as different as 
well differentiated carcinomas that have a very good prognosis 
and undifferentiated carcinomas or ATC that are among the 
most aggressive human cancers. As yet, the molecular players 
sustaining such different behavior are largely unknown. In this 
dissertation, we have demonstrated that Twist1 is up-regulated 
in ATC samples. Overall Twist1 up-regulation in ATC is more 
prominent at the RNA than at the protein level. It is possible 
that Twist1 overexpression is affected not only at the 
transcriptional level but also at the post-transcriptional level.  
  Twist1 up-regulation was associated with mitotic 
index, as determined by Ki67/MIB1. However, the fact that 
Twist1 did not influence cell proliferation in cultured cells 
suggests that it is not directly involved in controlling cell 
proliferation.  
  In ATC samples, Twist1 positivity also correlated 
with markers of mesenchymal transition (fusocellular 
phenotype) and malignancy (p53 positivity); however, 
correlation with p53 expression was not demonstrated in 
cultured thyroid cancer cells because Twist1-positive (OCUT-2, 
8505C, and CAL62) and Twist1-negative (TPC-1, BCPAP, 
NIM, ACT-1, SW1736) cells both had either high (8505C, 
ACT-1) or low/undetectable (CAL62, OCUT-2, TPC-1, 
BCPAP, NIM, SW1736) p53 expression (data not shown). 
  Twist1 expression is responsive to Wnt-1, IGF-I, 
and nuclear factor B (NF-κB) signaling. Elements of the Wnt 
pathway, particularly CTNNB1 (the gene coding β-catenin), 
were found to be mutated in PDC and ATC. Moreover, NF-κB 
is activated in human thyroid cancer cells, in particular in ATC. 
Therefore, both the Wnt-1/ β-catenin and NF- κB pathways are 
good candidates as mediators of Twist1 up-regulation in ATC. 
  Although a number of direct and indirect targets have 
been identified in recent years, the exact mechanisms through 
which Twist1 contributes to tumorigenesis are still largely 
unknown. To uncover the molecular mechanisms underlying 
Twist1 biological effects in thyroid cancer cells, we have 
performed a gene expression profile of Twist1 overexpressing 
cells. Gene signature obtained enriched for genes involved in 
invasion, migration and apoptosis consistent with the role of 
Twist1 in anaplastic thyroid cancer cells. Indeed the genes 
further studied were: ADAMTS1, ADAMTS5, ARHGDIB, 
ARGHPA9, CD24, DAPK1, GPR65, HS6ST2, KRT15, ID4, 
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MTSS1, PAPLN, PDZK1, PDZK1IP1, PCDH7, PKP2, 
PREX1, RHOB, TACTSD1 and WASF3. 
  In particular several genes studied (i.e. ARHGDIB, 
ARGHPA9, PREX1, RHOB) are members of the Rho pathway. 
Overexpression of Rho GTPases in human tumors often 
correlates with a poor prognosis. Furthermore, coordinated Rho 
GTPase signaling is considered to be part of mechanism 
underlying tumor cell invasion (Street et al. 2011).  
One of the highly upregulated gene in TPC Twist1 
transfected cells is HS6ST2, a member of the heparan sulfate 
(HS) sulfotransferase gene family. Heparan sulfate 
proteoglycans are ubiquitous components of the cell surface, 
extracellular matrix, and basement membranes, and interact 
with various ligands to influence cell growth, differentiation, 
adhesion, and migration. HS6ST2, catalyze the transfer of 
sulfate to HS (Song et al. 2011). 
Another gene of particular interest is ID4. ID proteins 
(ID-1 to 4) are dominant negative regulators of basic helix-
loop-helix transcription factors. They play a key role during 
development, preventing cell differentiation while inducing cell 
proliferation. They are poorly expressed in adult life but can be 
reactivated in tumorigenesis. Several evidences indicate that ID 
proteins are associated with loss of differentiation, unrestricted 
proliferation and neoangiogenesis in diverse human cancers 
(Dell’Orso et al. 2010).  
Among the genes overexpressed in TPC Twist1 
transfected cells we have isolated PDZK1 and its interacting 
protein PDZK1IP1 (MAP17). PDZK1IP1 is a small 17 kDa 
non-glycosylated membrane protein found overexpressed in a 
great variety of human carcinomas. Immunohistochemical 
analysis of PDZK1IP1 during cancer progression shows, at 
least in prostate and ovarian carcinomas, that overexpression of 
the protein strongly correlates with tumoral progression. 
Moreover, it was described that PDZK1IP1 promoter is 
activated by different oncogenes (Guijarro et al. 2007).  
Another gene upregulated in TPC Twist1 transfected 
cells is the epithelial cell adhesion molecule TACSTD1 
(EpCAM). TACSTD1 is a membrane glycoprotein that is 
highly expressed on most carcinomas and therefore of potential 
use as a diagnostic and prognostic marker for a variety of 
carcinomas. Recently, TACSTD1 has been identified as an 
additional marker of cancer-initiating cells. Furthermore, 
TACSTD1 abrogates E-cadherin mediated cell–cell adhesion 
thereby promoting metastasis (van der Gun et al. 2010).  
Twist1 upregulated CD24 mRNA. CD24 is an antigen 
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overexpressed in various tumor types and has been shown to be 
involved in tumor cell migration, invasion, and metastasis. 
CD24 has been shown to recruit adhesion molecules to lipid 
rafts, thereby contribuiting to tumor cell migration, 
dissemination and metastasis (Bretz, 2011). 
Consistent with the biological role of Twist1 in ATC, 
we found upregulated in TPC Twist1 transfectants compared to 
control cells, WASF3. This gene encodes a member of the 
Wiskott-Aldrich syndrome protein family. The gene product is 
a protein that forms a multiprotein complex that links receptor 
kinases and actin. Binding to actin occurs through a C-terminal 
verprolin homology domain in all family members. The 
multiprotein complex serves to transduce signals that involve 
changes in cell shape, motility or function. Inactivation of the 
WASF3 gene in prostate cancer cells leads to suppression of 
tumorigenicity and metastases (Teng et al. 2010). 
In conclusion, we have identified a set of 20 genes that 
mediates Twist1 biological effects in thyroid cancer. Further 
studies are on going in our laboratory to test the expression of 
the set of 20 Twist1 target genes in thyroid carcinoma samples. 
Based on the results obtained, for selected genes, when 
commercially antibodies are available, we will further perform 
western blot and immunohistochemistry studies. Other, studies 
are on going in our laboratory to investigate the effects of the 
silencing of HS6ST2, ID4, PDZK1 PDZK1IP1 and TACSTD1 
genes on cell migration and invasion of TPC Twist1, OCUT-2 
and CAL62 cells. Finally, a future direction of our work will be 
to verify if Twist1 binds to the promoter of selected genes. 
Possible binding sites for Twist1 are E-box (5’-CANNTG-3’) 
sequence motif. We will search in the promoter of the genes 
isolated in the screening, E-boxes sites using Match program 
(www.gene-regulation.com). We envisage the possibility for 
selected genes to perform chromatin immunoprecipitation. 
Identification of genes downstream transcription factor 
is important for clinical translation of basic research. Indeed, 
despite the growing evidences linking EMT to metastasis in 
various human cancers, therapeutically targeting EMT may be 
difficult. Directly inhibiting the transcription factors that drive 
EMT is currently infeasible, as targeting large binding 
interfaces is not amenable to small-molecule inhibition. 
Instead, downstream targets of these transcription factors 
essential for their role in invasion and metastasis are more 
realistic targets of therapeutic intervention. 
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6. CONCLUSIONS 
 
  Anaplastic thyroid carcinoma (ATC) ranks among 
the most lethal human malignancies. Here, we showed that 
ATCs up-regulate Twist1 with respect to normal thyroids as 
well as to poorly and well differentiated thyroid carcinomas. 
Knockdown of Twist1 by RNA interference in ATC cells 
reduced cell migration and invasion and increased sensitivity to 
apoptosis. The ectopic expression of Twist1 in thyroid cells 
induced resistance to apoptosis and increased cell migration and 
invasion. Finally, we have identified a set of 20 genes that 
mediates Twist1 biological effects. Further studies of each of 
these genes and of the pathway activated could lead to the 
discoveries of novel therapeutic target for ATC. 
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Context: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human tumors; it is
characterized by chemoresistance, local invasion, and distant metastases. ATC is invariably fatal.
Objective: The aim was to study the role of TWIST1, a basic helix-loop-helix transcription factor,
in ATC.
Design: Expression of TWIST1 was studied by immunohistochemistry and real-time PCR in normal
thyroids and well-differentiated, poorly differentiated, and ATC. The function of TWIST1 was
studied by RNA interference in ATC cells and by ectopic expression in well-differentiated thyroid
carcinoma cells.
Results: ATCs up-regulate TWIST1 with respect to normal thyroids as well as to poorly and well-
differentiated thyroid carcinomas.KnockdownofTWIST1byRNA interference inATCcells reduced
cellmigrationand invasionand increased sensitivity toapoptosis. Theectopic expressionof TWIST1
in thyroid cells induced resistance to apoptosis and increased cell migration and invasion.
Conclusions: TWIST1 plays a key role in determining malignant features of the anaplastic pheno-
type in vitro. (J Clin Endocrinol Metab 96: E772–E781, 2011)
Thyroid neoplasms include a broad spectrum of histo-types, ranging from benign adenomas to differenti-
ated papillary and follicular, poorly differentiated, and
rapidly growing anaplastic carcinomas (1, 2). Papillary
thyroid carcinoma (PTC) far outnumbers the other mor-
phological subtypes and is characterized, in general, by an
indolentphenotypewitha10-yr survival rateofup to90%
(1, 2). Poorly differentiated carcinomas (PDC) include a
heterogeneous group of neoplasms with morphological
features and clinical characteristics intermediate between
those of well-differentiated and anaplastic carcinomas (1,
2). Anaplastic thyroid carcinomas (ATC) represent less
than2%ofall thyroid cancersbut are responsible formore
than 50% of thyroid cancer mortality, with a mean sur-
vival time from diagnosis of 4–12 months (3). ATC is
highly invasive, and themajority of ATCpatients die from
suffocation due to locoregional disease extension or be-
cause of overwhelmingdistantmetastatic disease. Surgical
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treatment, radiotherapy, and chemotherapy, based pri-
marily on doxorubicin and cisplatin, show little efficacy in
ATC patients (3, 4). ATC cells feature a highly mitogenic
and motile phenotype and epithelial-mesenchymal tran-
sitionandare refractory toapoptotic cell death (3, 4).ATC
features genetic lesions that are typical of a well-differen-
tiated carcinoma, namely BRAF or RAS point mutations.
Only a few genetic lesions have been identified exclusively
in ATC, i.e. p53, PI3KCA, or -catenin mutations (5–8).
Therefore, the molecular mechanisms driving the estab-
lishment of the highly aggressive anaplastic phenotype are
still largely unknown (2–5).
We have recently identified, through a cDNAmicroar-
ray analysis, a gene expression signature that is associated
with the highly proliferative and aneuploid ATC pheno-
type (9). Among the genes highly up-regulated in ATC vs.
normal tissue and PTC, we have isolated TWIST1.
TWIST1 is a highly conserved basic helix-loop-helix tran-
scription factor that plays a key role in mesodermal, myo-
blast, and osteoblast differentiation (10, 11). Mutational
inactivation of TWIST1 is responsible for the Saethre-
Chotzen syndrome, an autosomal dominant disorder
characterized by premature fusion of the cranial sutures,
skull deformations, limb abnormalities, and facial dys-
morphism (12). TWIST1 plays an important role in the
development and progression of human cancer. TWIST1
overexpression is reported in many human tumors, in-
cluding rhabdomyosarcoma, glioma, melanoma, breast,
gastric, and prostate carcinomas (13, 14). Elevated
TWIST1 protein levels are associated with advanced tu-
mor stage and poor prognosis in several cancer types (14,
15). TWIST1 promotes epithelial-mesenchymal transition
(16, 17). TWIST1 gene amplification is associated with re-
sistance to chemotherapeutic agents (18, 19). Finally,
TWIST1 inhibits premature senescence in cancer cells (20).
Here we report that TWIST1 plays a key role in the
ATC phenotype in vitro and suggest that it may mediate
chemoresistance of ATC cells.
Materials and Methods
Reagents
Staurosporine and cisplatin were obtained from Sigma-
Aldrich (St. Louis, MO).
Cell cultures
Human cell lines (S11N, P5 4N, 8505C, CAL62, SW1736,
OCUT-2, ACT-1, TPC-1, BCPAP) (21–23), rat cell lines (PC
RET/PTC1, PCRET/PTC3, PC v-HRAS, PC-BRAF-V600E, PC-
TRK-T1, PC v-RAF, PC v-MOS, PC E1A, and PC E1A-v-RAF)
(24, 25), and culture conditions are detailed in the Supplemental
Data (publishedonTheEndocrine Society’s JournalsOnlineweb
site at http://jcem.endojournals.org).
Tissue samples
Tumors and normal thyroid (NT) tissue samples for immu-
nohistochemical analysis were retrieved from the files of the Pa-
thologyDepartment of theHospital Central deAsturias (Oviedo
University, Asturias, Spain) and of the Hospital Clinico Univer-
sitario de Santiago deCompostela (Santiago deCompostelaUni-
versity, Galicia, Spain). Tumors andNT tissue samples for RNA
extractionandquantitativeRT-PCRwere retrieved fromthe files
of the Department of Surgery, University of Pisa (Pisa, Italy).
Case selection was based on the histological findings and on the
availability of adequate material for RNA extraction. All histo-
logical diagnoses were reviewed by two blinded pathologists
(G.G.-R. and C.D.) according to the latest recommendations
about diagnostic features of PTC, PDC, and ATC (26–28). PDC
were defined as malignant tumors of follicular cells displaying
predominant solid/trabecular/insular growth patterns, high-
grade features such asmitoses (more than three to fivemitoses
10 high power field) and/or necrosis and convoluted nuclei, with
or without concurrent differentiated components of the follicu-
lar or papillary type. ATC were defined as tumors displaying
admixtures of spindle, pleomorphic giant, and epithelioid cells;
high mitotic activity; extensive coagulative necrosis with irreg-
ular borders; and infiltration of vascular walls often accompa-
nied by obliteration of the vascular lumina. After microscopic
examinationof exhaustively sampled specimens, 32 tumorswere
classified as PTC, 93 as PDC, and 56 as ATC. Processing of
samples and of patient information proceeded in agreementwith
review board-approved protocols.
Immunohistochemistry
Formalin-fixed and paraffin-embedded 3- to 5-m-thick tu-
mor sections were deparaffinized, placed in a solution of abso-
lute methanol and 0.3% hydrogen peroxide for 30 min, and
treated with blocking serum for 20 min. The slides were incu-
bated with mouse monoclonal antibodies against TWIST1 (sc-
81417; Santa Cruz Biotechnology, Santa Cruz, CA) and pro-
cessed according to standard procedures. Negative controls by
omitting the primary antibody were included in the assay. Cases
were scored as positive when unequivocal brown staining was
observed in the nuclei of tumor cells. Immunoreactivity was ex-
pressed as the percentage of positively stained target cells in four
intensity categories (, no staining; , low/weak; , moder-
ate/distinct; , high/ intense). Twist1 score values were in-
dependently assigned by two blinded investigators (G.G.-R. and
C.D.), and a consensus was reached on all scores used for
computation.
RNA extraction and expression studies
Total RNA was isolated with the RNeasy Kit (QIAGEN,
Crawley, West Sussex, UK). The quality of the RNAs was ver-
ified by the 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany); only samples with an RNA integrity number
value above 7were used for further analysis. Real-time PCRwas
performed as detailed in the Supplemental Data: for the calcu-
lation of expression fold changes, sample 1 represented each
single tumor sample, and sample 2was the average of all (n22)
NTs.Microarraymethods are also reported in the Supplemental
Data.
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Protein studies
Immunoblotting was carried out according to standard pro-
cedures. Anti-TWIST1 (sc-81417) and anti-p53 (Pab 240)
monoclonal antibodies were from Santa Cruz Biotechnology;
monoclonal anti--tubulin antibody was from Sigma-Aldrich;
anti-cleaved (Asp175) caspase-3 p17 and p19 fragments poly-
clonal (5A1) antibody was from Cell Signaling Technology, Inc.
(Beverly, MA). Secondary antimouse and antirabbit antibodies
coupled to horseradish peroxidase were from Santa Cruz
Biotechnology.
RNA silencing
Small inhibitor duplex RNA targeting TWIST1 (no. 3, 5, and
7) and the scrambled control [nonspecific small interfering RNA
(siRNA) duplex containing the same nucleotides but in irregular
sequence] have been described previously (16) and were chem-
ically synthesized by Sigma-Aldrich. Based on its higher silencing
efficiency, TWIST1 siRNA 3 (hereafter referred to as TWIST1
siRNA) was selected and used throughout the paper. The day of
transfection, 1105 cellswere incubatedwith50nMsiRNAand
electroporated usingMicroPorator (MP-100, Digital Bio; Euro-
clone,Milan, Italy) according to themanufacturer’s instructions.
Cellswere harvested24, 48, and72hafter transfection, counted,
and analyzed for protein expression.Methods used to determine
cell viability, motility, and invasion are detailed in the Supple-
mental Data.
TWIST1 transfection
The pcDNA 3-TWIST1 vector is described elsewhere (29).
TPC-1 cellswere transfectedbyusing theLipofectamineReagent
(Invitrogen, Carlsbad, CA) according to the instructions of the
manufacturer. Two days later, G418 (Invitrogen) was added at
a concentration of 1.2 mg/ml. Two mass populations of several
clones and three independent cell clones were isolated, ex-
panded, and screened for TWIST1 expression by Western blot
and RT-PCR analysis. One mass population and two cell clones
transfectedwith the control pcDNA3 vectorwere expanded. To
generate stable shRNA (short hairpin RNA)-expressing cell line,
CAL62 cells were transfected with shTWIST1 and shLUC vec-
tors (20) by using the Lipofectamine reagent (Invitrogen) ac-
cording to the instructions of the manufacturer. Two days later,
puromycin (Invitrogen) was added at a concentration of 0.5 mg/
ml. Mass populations and several cell clones were isolated, ex-
panded, and screened for TWIST1 knockdown byWestern blot
and RT-PCR analysis. Methods used to determine cell viability,
motility, and invasion are detailed in the Supplemental Data.
Statistical analysis
Statistical analyses were carried out using the GraphPad In-
Stat softwareprogram(version3.06.3;GraphPadSoftware, Inc.,
San Diego, CA). All P values were two-sided, and differences
were significant when P  0.05.
Results
Up-regulation of TWIST1 in ATC
We evaluated TWIST1 expression levels by immuno-
histochemistry in 157 human tissues including: 15NT, 13
PTC, 88 PDC, and 41 ATC samples. Representative im-
munohistochemical staining is shown in Fig. 1A, and the
entire dataset is reported inTable 1.TWIST1was virtually
undetectable in NT, PTC, and PDC samples. In contrast,
49% of the ATC samples (20 of 41) were positive for
TWIST1 expression. Positivity ranged between at least 5
and nomore than 25% () to at least 60% () of cells
(Fig. 1A and Table 1); no staining was observed in the
absence of the primary antibody (data not shown).
TWIST1 positivity correlated with moderate/high prolif-
eration rate assessed by Ki67/MIB1 immunoreactivity
(Freeman-Haltonextensionof theFisher exactprobability
test, P 0.048) (Supplemental Table 1). There was also a
trend for a significant association with up-regulation of
the cell cycle regulated minichromosome maintenance 5
protein (Freeman-Halton extension of the Fisher exact
probability test, P  0.11) (data not shown). TWIST1
expression correlated with the fusocellular ATC pheno-
type and inversely correlated with the epithelioid ATC
phenotype (2 test, P  0.0002; Freeman-Halton exten-
sion of the Fisher exact probability test, P 0.0001) (Sup-
plemental Table 1), suggesting that TWIST1 is involved in
mesenchymal transition of ATC cells. Accordingly, there
was a trend toward a correlation between TWIST1 up-
regulation and lack of -catenin staining at the plasma
membrane (Freeman-Halton extension of the Fisher exact
probability test, P  0.119) (data not shown). Finally,
TWIST1 positivity correlated with p53 positivity (Free-
man-Halton extension of the Fisher exact probability test,
P  0.030) (Supplemental Table 1).
To determine whether TWIST1 up-regulation also oc-
curred at the RNA level, we examined an independent set
of ATC (n 15), PDC (n 4), PTC (n 19), andNT (n
22) samples byquantitativeRT-PCR.As shown inFig. 1B,
TWIST1 mRNAwas up-regulated by more than 5-fold in
about 50% (seven of 15) of the ATC samples, with values
greater than10-fold in13%(twoof15)of them.NT,PTC,
and PDC samples expressed lower TWIST1 levels com-
pared with ATC (P  0.001) (Fig. 1B).
In vertebrates, there are two TWIST genes, TWIST1 and
TWIST2 (also known as Dermo1), and their encoded pro-
teins showan identity in thebasichelix-loop-helixdomainof
more than 90% (20). Therefore, we alsomeasured TWIST2
expression by quantitative RT-PCR in thyroid tissue
samples. TWIST2 was overexpressed in some cases, but
at a lower extentwith respect to TWIST1 (Supplemental
Fig. 1). Indeed, TWIST2was up-regulated bymore than
2-fold in only about half of the ATC samples (four of
nine), with values greater than 5-fold in only one of nine
ATC samples. No PTC sample up-regulated TWIST2
(Supplemental Fig. 1A).
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Up-regulation of TWIST1 in thyroid cancer cell
lines
We analyzed TWIST1 expression in cultured human
thyroid cells. To this aim, we used primary cultures of NT
follicular cells (P5 4N and S11N) and a panel of PTC
(TPC-1, NIM, BCPAP) and ATC (ACT-1, OCUT-2,
8505C, SW1736, CAL62) cell lines.Western blot analysis
showedup-regulation of a band at approximately 26 kDa,
which corresponded to the TWIST1 protein only in the
ATC cell lines OCUT-2, 8505C, and CAL62 (Fig. 1C).
TWIST1 expression was lower in the other ATC cells
and in all the PTC cell lines analyzed, whereas it was
undetectable in NT cells (Fig. 1C). RT-PCR analysis
confirmed the Western blot results (data not shown).
Finally, CAL62 and BCPAP also up-regulated TWIST2
mRNA by more than 2-fold with respect to NT cells
(Supplemental Fig. 1B).
To confirm TWIST1 expression in a model cell sys-
tem and to start exploring whether TWIST1 up-regu-
lation correlated with loss of differentiation or with an
aggressive tumor phenotype, we used a panel of rat thy-
roid follicular Fischer rat-derived thyroid follicular cell
TABLE 1. TWIST1 expression in thyroid samples
(n  157)
Tissue
TWIST1 positivity, % of positive samples
(positive/total samples)
NT 0% (0/15)
PTC 0% (0/13)
PDC 0% (0/88)
ATC 49% (20/41)  17% (7/41)
 15% (6/41)
 17% (7/41)
, 5 to 25% of positive cells; , 25 to 60% of positive cells;
, 60% of positive cells.
FIG. 1. Expression of TWIST1 in thyroid tissue samples and in cell lines. A, Immunohistochemical analysis of TWIST1 protein expression in normal
and malignant thyroid tissues. Representative histological sections from NT (20 magnification), classical PTC (CL-PTC; 10 magnification),
follicular variant PTC (FV-PTC; 20 magnification), PDC (4 magnification), and ATC (20 and 4 magnification) stained with a mouse
monoclonal anti-TWIST1 antibody are shown. The NT, CL-PTC, FV-PTC, and PDC sections were negative for TWIST1, whereas the two ATC cases
featured high/intense immunoreactivity levels (, e.g. 60% of cells); in particular, the ATC sample at 20 magnification showed 65% of
positive cells, whereas the ATC at 4 magnification showed 85% of positive cells. B, Quantitative RT-PCR of TWIST1 mRNA in NT (n  22), PTC
(n  19), PDC (n  4) and ATC (n  15) snap-frozen tissue samples. The level of TWIST1 expression in each sample was measured by comparing
its fluorescence threshold with the average fluorescence threshold of the NT samples. The average results of triplicate samples are plotted. C, NT
follicular cells (P5 4N and S11N), PTC (TPC-1, NIM, and BCPAP), and ATC (ACT- 1, OCUT-2, 8505C, SW1736, and CAL62) cell lines were analyzed
by immunoblot using a mouse monoclonal anti-TWIST1 antibody. Anti -tubulin monoclonal antibody was used as a control for equal protein
loading. D, Immunoblot of TWIST1 expression in rat thyroid PC cells expressing the indicated oncogenes. ***, P  0.001.
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line PC CI 3 (PC) cells adoptively expressing various
oncogenes (PC-RET/PTC1, PC-RET/PTC3, PC-v-HRAS,
PC-TRK-T1, PC-v-RAF, PC-BRAF V600E, PC-E1A,
PC-E1A-v-RAF, and PC-v-MOS). Although the expres-
sion of v-MOS and of the E1A/v-RAF combination en-
abled PC cells to grow in semisolid medium and to in-
duce tumors in athymicmice, the expression of the RET/
PTC1/3,HRAS, TRK,RAF (v-RAF and BRAF) and E1A
oncogenes only caused loss of differentiation without
fostering a tumorigenic phenotype (24, 25). Figure 1D
shows that TWIST1 was only expressed in the PC cells
transformed by v-MOS, and at lower levels by E1A 
v-RAF. Therefore, TWIST1 up-regulation correlated
with malignant phenotype rather than loss of differen-
tiation of rat thyroid cells.
Knockdown of TWIST1 induces apoptosis of ATC
cells
We evaluated the effects of TWIST1 ablation in ATC
cells by RNA interference. We initially tested, byWestern
blot in CAL62 cells, the efficiency of TWIST1 ablation
using three different siRNA (no. 3, 5, and7) (16). TWIST1
FIG. 2. Effects of TWIST1 knockdown in ATC cells. A, CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled
siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated antibodies. B,
CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled siRNA and counted at different time points. Values
represent the average of triplicate experiments  95% confidence intervals. C, CAL62 and 8505C cells were transfected with TWIST1 siRNA or
with scrambled siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated
antibodies. D, The indicated cell lines were transfected with TWIST1 siRNA or scrambled siRNA; after 48 and 72 h, cells were collected by
trypsinization, stained for 10 min with trypan blue, and counted in triplicate. The percentage of trypan blue excluding cells compared with cells
transfected with siRNA scrambled is reported  SD. ***, P  0.001.
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siRNA 3 (hereafter named TWIST1 siRNA) reduced
TWIST1 protein levels of about 60% (Fig. 2A) and there-
fore was selected for further experiments, whereas the
other two siRNAs (5 and 7) were less effective, with
siRNA 5 being practically devoid of any effect and siRNA
7 depleting TWIST1 protein by less than 30% (Supple-
mental Fig. 2).
We knocked down TWIST1 by transient siRNA
TWIST1 transfection in CAL62, 8505C, and OCUT-2
cells. As shown in Fig. 2A, a TWIST siRNA silenced the
TWIST1protein starting at 24hafter transfection, and the
effect lasted up to 72 h, whereas a scrambled siRNA con-
trol had no effect (Fig. 2A). Thus, cells were transfected
with TWIST1 siRNA or with scrambled siRNA and
counted at different time points (24, 48, and 72 h) (Fig.
2B). Seventy-two hours after transfection, CAL62 cells
transfected with scrambled siRNA numbered 259 103,
whereas those transfectedwithTWIST1siRNAnumbered
81  103 (P 0.0008); 8505C cells transfected with
scrambled siRNA numbered 679  103, whereas those
transfected with TWIST1 siRNA numbered 351  103
(P  0.0001); OCUT-2 cells transfected with scrambled
siRNA numbered 278  103, and those transfected with
TWIST1 siRNA numbered 176 103 (P
0.0009) (Fig. 2B). It should be noted that
CAL62, but not 8505C and OCUT-2, ex-
pressed detectable levels of TWIST2 (Sup-
plemental Fig. 1B). Thus, it is feasible, be-
cause of the high degree of homology
between TWIST1 and TWIST2, that the ef-
fects of TWIST1 siRNAobserved inCAL62
cells were due to the combined inhibition of
TWIST1 andTWIST2. Accordingly, at 24 h
after siRNA transfection, TWIST2 mRNA
was down-regulated by 1.8-fold in CAL62
(data not shown).
At 48 and 72 h, siRNATWIST1 induced
cell apoptosis of CAL62 and 8505C cells as
measured by immunoblot with an antibody
for the cleaved products of caspase 3 (Fig.
2C). Accordingly, the percentages of trypan
blue excluding (viable) cells, of CAL62
transfected with TWIST1 siRNA 48 and
72h after transfection,were of 69 and32%,
respectively, with respect to scrambled con-
trol, confirming that TWIST1 depletion re-
duced thyroid cancer cell viability (P 
0.001) (Fig. 2D).
Because TWIST1 has been associated
with premature senescence of cancer cells
(20), we performed a senescence-associated
-galactosidase (SA--gal) stainingassayon
siRNA TWIST1-treated cells. Seventy-two
hours after transfection with TWIST1 siRNA, the per-
centage of SA--gal-positive cells was 1.3%, whereas it
was 0.7% in scrambled siRNA transfected cells. As a pos-
itive control, the percentage of SA--gal-positive cells was
38% in normal human diploid fibroblasts treated with
Etoposide (Sigma-Aldrich) (data not shown). Thus, al-
though significant, senescence induced by TWIST1
knockdown involved only a minor fraction of ATC cells.
Knockdown of TWIST1 impairs cell migration and
invasion of ATC cells
Weevaluated themigration (by awound-healing assay)
and invasion (by a Matrigel invasion assay) ability of
TWIST1 siRNA-transfected cells compared with scram-
bled siRNA-transfected cells. As shown in Fig. 3A, 8505C
and OCUT-2 cells transfected with the scrambled control
efficiently migrated into the wound; in contrast, cells
transfected with TWIST1 siRNA had a greatly reduced
migrating ability (P  0.001). Furthermore, cells trans-
fected with TWIST1 siRNA had a reduced ability to in-
vade Matrigel compared with control cells (P  0.001)
(Fig. 3B).
FIG. 3. Effects of TWIST1 knockdown on ATC cell migration and invasion. A, Cells were
transfected with TWIST1 siRNA or scrambled siRNA; a scraped wound was introduced,
and cell migration into the wound was monitored at 24 h. B, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage
of wound closure of triplicate areas  SD. C, Cells were transfected with TWIST1 siRNA
or scrambled siRNA; after transfection, cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and
cells on the lower surface were stained and counted. Invasive ability was expressed as
number of invaded cells. Values represent the average of triplicate experiments  SD.
***, P  0.001.
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Effects of stable silencing of TWIST1 in CAL62 cells
We stably transfected CAL62 cells with an shTWIST1
plasmid or with shLUC control (20). After antibiotic se-
lection, cells were screened by Western blot for TWIST1
expression. Amass population (mp) (shTWIST1mp)with
a TWIST1 knockdown of approximately 52% was used
for further study (Supplemental Fig. 3A). Consistent with
data obtained upon transient TWIST1 silencing (Fig. 2),
shTWIST1 mp cells showed decreased migration and in-
vasion abilitywith respect to shLUC-transfected cells (P
0.001) (Supplemental Fig. 3, B–D). To address effects of
TWIST1 knockdown on chemosensitivity, cells were
treated with cisplatin (200 or 1000 nM) or staurosporine
(300or 500nM) and counted at 24h.Upon treatmentwith
cisplatin (1000 nM) or staurosporine (300–500 nM),
shTWIST1 mp cells had a decreased viability compared
with control cells (P  0.001) (Supplemental Fig. 3E).
Finally, the number of colonies formed
in semisolid medium (soft agar) was
also reduced by 2-fold compared with
the shLUCmp control (P 0.05) (Sup-
plemental Fig. 3F). Thus, TWIST1 ab-
lation in vitro affected several hall-
marks of malignancy of CAL62 cells,
including anchorage-independent pro-
liferation, survival, and invasion.
Ectopic TWIST1 promotes cell
migration and invasion of PTC
cells
PTC cells, TPC-1, which have low
endogenous levels of TWIST1, were
transfected with a TWIST1-express-
ing plasmid (pcDNA-TWIST1) or
with the empty vector (pcDNA).Mass
populations and cell clones were se-
lected in G418 (1.2 mg/ml). TWIST1
expression was increased (4- to 13-
fold) in all the cell lines transfected
with TWIST1 comparedwith the con-
trols (Fig. 4A). Growth rate was sim-
ilar in TWIST1- and vector-trans-
fected control cell lines (data not
shown). Therefore, we studied cell
migration using thewound closure as-
say. As shown in Fig. 4, B and C, mi-
gration rate was higher in TWIST1-
transfected cells than in control cells
(P  0.05). We next seeded TWIST1-
transfected and control cells into the
top chamber of transwells and evalu-
ated their ability to invade Matrigel.
TPC-1 cells had basal levels of inva-
siveness, and TWIST1 overexpression further increased
this ability by 4- to 6-fold (P  0.001) (Fig. 4D). Thus,
TWIST1 stimulated cell motility and invasion, although
wound closure and Matrigel invasion extent were not
directly proportional to the TWIST1 expression levels
(Fig. 4). These findings suggest that the TWIST1 ex-
pression level is not the only molecular determinant of
thyroid cancer cell invasive phenotype.
Ectopic TWIST1 protects PTC cells from apoptosis
We treated TPC-1 cells transfected with TWIST1 or
control vector with different concentrations of cisplatin
(200, 1000, and 2000 nM) and counted cell number at
24 h. As shown in Fig. 5A, cell viability was higher in
TWIST1-transfected than in control cells upon treat-
ment with the highest drug dose (P  0.05). Moreover,
FIG. 4. Effects of TWIST1 overexpression on TPC-1 cell migration and invasion. A, Expression
levels of TWIST1 in TPC-1-transfected cells. After G418 selection, cells were lysed and blotted
with the indicated antibodies. B, A scraped wound was placed on the confluent monolayer of
TPC-1 transfected with TWIST1 or the empty vector, and the cell migration into the wound
was monitored at 24 h. Arrows indicate the site of wound closure. C, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage of
wound closure of triplicate areas  SD. D, Cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and cells
on the lower surface were stained and counted. Invasive ability was expressed as number of
invaded cells. Values represent the average of triplicate experiments  SD. *, P  0.05;
**, P  0.01; and ***, P  0.001.
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the amount of caspase 3 cleaved product was lower in
TWIST1-transfected than in control cells (Fig. 5B).
Finally, we searched an Affymetrix microarray-based
data set for genes that were previously reported to be
TWIST1 targets and related to cell cycle and apoptosis
control (30). TWIST1-overexpressing cells (TPC-1
TWIST1 mp1, TWIST1 mp2, and TWIST1 Cl2) up-reg-
ulated (P 0.05), with respect to pcDNAmp control, the
expression of AKT2 (average fold change  SD, 2  0.5)
and BCL-2 (average fold change  SD, 1.67  0.2),
whereas they down-regulated the expression of p21CIP/
WAF1 (average fold change  SD, 0.7  0.3). TWIST1
overexpression, instead, did not significantly change the
expression of p14ARF, BAX, and TIMP1 in our system
(data not shown).
Discussion
Thyroid cancer includes tumor types as different as well-
differentiated carcinomas that have a very good prognosis
and undifferentiated carcinomas or ATC that are among
the most aggressive human cancers. As yet, the molecular
players sustaining such different behavior are largely un-
known. Here, we demonstrate that TWIST1 is up-regu-
lated in ATC samples. Overall TWIST1 up-regulation in
ATC is more prominent at the RNA than at the protein
level. It is possible that TWIST1 overexpression is affected
not only at the transcriptional level but also at the post-
transcriptional level. TWIST1 up-regulation was associ-
ated with mitotic index, as determined by Ki67/MIB1.
However, the fact that TWIST1 did not influence cell pro-
liferation in cultured cells suggests that it is not directly
involved in controlling cell proliferation. In ATC samples,
TWIST1 positivity also correlated with markers of mes-
enchymal transition (fusocellular phenotype) and malig-
nancy (p53 positivity); however, correlation with p53 ex-
pression was not demonstrated in cultured thyroid cancer
cells because TWIST1-positive (OCUT-2, 8505C, and
CAL62) and TWIST1-negative (TPC-1, BCPAP, NIM,
ACT-1,SW1736)cellsbothhadeitherhigh (8505C,ACT-1)
or low/undetectable (CAL62, OCUT-2, TPC-1, BCPAP,
NIM, SW1736) p53 expression (Supplemental Fig. 4).
In vitro cellular models confirmed the role of
TWIST1 in determining the ATC phenotype and iden-
tified the ATC features that were sustained by TWIST1
up-regulation. TWIST1 up-regulation did not correlate
with loss of differentiation; indeed, it did not occur in
PC cells that lost differentiation secondary to the
expression of various oncogenes. Rather, TWIST1
overexpression correlated with a malignant phenotype
being present in tumorigenic PC-v-MOS and PC-
E1Av-RAF cells (24). Moreover, TWIST1 expression
was necessary to counteract spontaneous ATC cell ap-
optosis and to sustain the invasive andmotile phenotype
of ATC cells. Accordingly, when overexpressed in PTC
cells, TWIST1 promoted cell migration and protected
cells from apoptosis. Given the high homology between
TWIST1 and -2, the TWIST siRNA also targeted
TWIST2 (1.8-fold), albeit at lower levels than TWIST1
(2.5-fold). Thus, it is possible that at least in CAL62
cells effects were due to the combined inhibition of
TWIST1 and TWIST2.
TWIST1 expression is responsive to Wnt-1 (31),
IGF-I (32), and nuclear factor B (NF-B) signaling
(33). Elements of the Wnt pathway, particularly
CTNNB1 (the gene coding -catenin), were found to be
mutated in PDC and ATC (34). Moreover, NF-B is ac-
tivated in human thyroid cancer cells, in particular inATC
(35). Therefore, both the Wnt-1/-catenin and NF-B
pathways are good candidates as mediators of TWIST1
up-regulation in ATC.
Up-regulation of TWIST1 is associated with cellular
resistance to anticancer drugs such as cisplatin, taxol, and
vincristine in various types of cancers (18, 19, 36). Here,
we show that TWIST1 overexpression protected thyroid
FIG. 5. Effects of TWIST1 overexpression on TPC-1 cell apoptosis. A,
The cells were treated with increasing doses of cisplatin and counted
24 h after treatment. Data are shown as percentage of inhibition of
cell viability. Values represent the average of three independent
experiments  SD. *, P  0.05; **, P  0.01; and ***, P  0.001. B,
The indicated cell lines were treated with increasing doses of cisplatin,
lysed, and blotted with the indicated antibodies.
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cancer cells from cell death induced by cisplatin and stau-
rosporine. This suggests that TWIST1may be exploited as
a molecular marker of the response of thyroid cancer to
chemotherapy.
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Supplemental Methods 
Cell cultures-Normal thyroid primary S11N cells were provided by H. Zitzelsberger 
(Department of Radiation Cytogenetics, Neuherberg, Germany) and P5 4N cells were provided 
by F. Curcio (Università di Udine, Udine, Italia) in 2003. 8505C and CAL62 cells were 
purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig, Germany) in 2006. SW1736 cells were obtained from N.E. Heldin (University 
Hospital, Uppsala, Sweden) in 2005. OCUT-2 and ACT-1 cells were provided by N. Onoda 
(Osaka University of Medicine, Osaka, Japan) in 2005. TPC-1 cells were obtained from M. 
Nagao (Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan) in 
1990. NIM cells were obtained from J. Fagin (Memorial Sloan Kettering Cancer Center, New 
York, NY) in 1993. BCPAP cells were obtained from N. Fabien (CNRS, Oullins, France) in 
1994. 8505C, SW1736 and CAL62 cells were DNA profiled by short tandem repeat analysis in 
2009 and shown to be unique and identical to those reported in Schweppe et al., 2008 (1, 2). 
The BCPAP cell line was genotyped as reported elsewhere Schweppe et al., 2008 (1). The TPC-
1 cell line was identified based on the unique presence of the RET/PTC1 rearrangement. S11N 
cells were grown in RPMI (Invitrogen, Groningen, The Netherlands) containing 20% fetal 
bovine serum; P5 4N were grown as previously described (3). The thyroid cancer cell lines were 
grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 10% fetal 
bovine serum. 
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The Fischer rat-derived differentiated thyroid follicular cell line PC Cl 3 (hereafter 
named “PC”) was grown in Coon’s modified Ham F12 medium supplemented with 5% calf 
serum and a mixture of six hormones (6H): thyrotropin (10mU/ml), hydrocortisone (10nM), 
insulin (10µg/ml), apo-transferrin (5µg/ml), somatostatin (10ng/ml), and glycyl-histidyl-lysine 
(10ng/ml) (Sigma-Aldrich, St. Louis, MO). PC adoptively expressing several oncogenes (PC 
RET/PTC1, PC RET/PTC3, PC v-HRAS, PC-BRAF-V600E, PC-TRK-T1, PC v-RAF, PC v-
MOS, PC E1A and PC E1A-v-RAF) have been described previously and cultured in the same 
medium as PC but without the 6H (4, 5). 
 
Cell culture methods- For cell viability determination, cells were collected by trypsinization, 
stained for 10 min with 0.4% trypan-blue (Sigma) according to manufacturer’s instructions, and 
counted in triplicate.  
For senescence-Associated-β-galactosidase staining, CAL62 (2x105) cells were 
transfected with TWIST1 siRNA or with scrambled control. Seventy-two h after transfection, 
the cells were washed twice with PBS, fixed with 2% formaldehyde and 0.2% glutaraldehyde in 
PBS, and washed twice in PBS. Then, cells were stained overnight in X-gal staining solution [1 
mg/ml X-gal, 40 mM citric acid/sodium phosphate (pH 6.0), 5 mM potassium ferricyanide, 5 
mM potassium ferrocyanide, 150 mM NaCl, 2 mM MgCl2] and stained cells were counted. 
Positive control was represented by normal human diploid fibroblasts IMR-90 treated with 
Etoposide 20 µM for 24 h. 
Cell invasion was examined using a reconstituted extracellular matrix (Matrigel, BD 
Biosciences, San Jose, CA). The cell suspension (1 x 105 cells per well) was added to the upper 
chamber of transwell cell culture chambers on a prehydrated polycarbonate membrane filter of 
8-µm pore size (Costar, Cambridge, MA) coated with 35 µg of Matrigel (BD Biosciences). The 
lower chamber was filled with 2.5% medium. After 12-h incubation at 37°C, non-migrating 
cells on the upper side of the filter were wiped-off. Invading cells were mounted on glass slides 
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using mounting medium and stained with Hoechst (Sigma). Cell migration was quantified by 
counting the number of stained nuclei in five individual fields in each Transwell membrane, by 
fluorescence microscopy, in triplicate.  
For wound closure, a wound was induced on the confluent monolayer cells by scraping 
a gap using a micropipette tip. Photographs were taken at 100 X magnification using phase-
contrast microscopy immediately after wound incision and 24 h later. Pixel densities in the 
wound areas were measured using the Cella software (Olympus Biosystem Gmb) and expressed 
as percentage of wound closure where 100% is the value obtained at 10h for control cells. 
For growth in semisolid medium, colony formation ability of CAL62 shLUC mp and 
CAL62 shTWIST1 mp cells was examined by soft agar assay. Briefly, 7 ml of FBS 
supplemented medium containing 0.5% noble agar were added to 60-mm cell culture dish and 
allowed to solidify (base agar). Next, 2x104 cells were mixed with 1.5 ml of FBS supplemented 
medium containing 0.83% noble agar and added to the top of base agar. The cells were then 
cultured for 14 days at 37°C under 5% carbon dioxide and colonies were counted. 
 
RNA extraction and expression studies - Total RNA was isolated with the RNeasy Kit (Qiagen, 
Crawley, West Sussex, UK). The quality of the RNAs was verified by the 2100 Bioanalyzer 
(Agilent Technologies, Waldbronn, Germany); only samples with RNA integrity number (RIN) 
value > 7 were used for further analysis. One µg of RNA from each sample was reverse-
transcribed with the QuantiTect® Reverse Transcription (Qiagen). For quantitative RT-PCR, we 
used the Human ProbeLibrayTM system (Exiqon, Denmark). TWIST1 primer sequences were: 
TWIST1 -F: 5’-GGC TCA GCT ACG CCT TCT C-3’ 
TWIST1 -R: 5’- CCT TCT CTG GAA ACA ATG ACA TCT-3’ 
PCR reactions were performed in triplicate and fold changes were calculated with the formula: 
2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the amplification fluorescent 
thresholds of the mRNA of interest and the mRNA of RNA polymerase 2 used as an internal 
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reference. Sample 1 represented each single tumor sample and sample 2 was the average of all 
(n. 22) normal thyroids.  
For microarrays, 10 µg purified total RNA from 3 TWIST1 TPC-1 transfectants 
(TWIST1 mp1, TWIST1 mp2, TWIST1 Cl2) and pcDNAmp2 control was transcribed into 
cDNA using Superscript RT (Invitrogen), in the presence of T7-oligo(dT)24 primer, 
deoxyribonucleoside  triphosphates (dNTPs), and T7 RNA polymerase promoter (Invitrogen). 
An in vitro transcription reaction was then performed to generate biotinylated cRNA which, 
after fragmentation, was used in a hybridization assay on Affymetrix U133 plus 2.0 GeneChip 
microarrays, according to manufacturer’s protocol (GeneChip 3' IVT Express Kit, Affymetrix). 
Normalization was performed by global scaling and analysis of differential expression was 
performed by Microarray Suite software 5.0 (Affymetrix). The final results were imported into 
Microsoft Excel (Microsoft). 
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Supplemental Results 
 
 
Figure 1: A: Quantitative RT-PCR of TWIST2 mRNA in NT (n=22), PTC (n= 19), and ATC 
(n=9) snap-frozen tissue samples. The level of TWIST2 expression in each sample was 
measured by comparing its fluorescence threshold with the average fluorescence threshold of 
the 22 NT samples. The average results of triplicate samples are plotted. B: Quantitative RT-
PCR of TWIST2 mRNA in normal human thyroid follicular cells (S11N), PTC (TPC-1, BCPAP 
and NIM) and ATC (8505C, SW1736, OCUT-2 CAL62, ACT- 1) cell lines. The level of 
TWIST2 expression in each sample was measured by comparing its fluorescence threshold with 
the fluorescence threshold of the human thyroid follicular cells (S11N). The average results of 
triplicate samples ± SD are plotted. 
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Figure 2: CAL62 were transfected with two different small inhibitor duplex RNA targeting 
TWIST1 (#5, #7) and the scrambled control. Cells were harvested 48 h after transfection, and 
analyzed for TWIST1 protein expression. Tubulin was used for normalization. 
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Figure 3: A Expression levels of TWIST1 and Tubulin in CAL62 cells transfected with 
shLUC or shTWIST1; B: A scraped wound was placed on the confluent monolayer of CAL62 
transfected with shTWIST1 or shLUC and the cell migration into the wound was monitored at 
the indicated time points. C: Wound closure was measured by calculating pixel densities in the 
wound area and expressed as percentage of wound closure of triplicate areas ± SD. D: CAL62 
transfected with shTWIST1or shLUC (1x105) were seeded in the upper chamber of transwells 
and incubated for 12 h; the upper surface of the filter was wiped clean and cells on the lower 
surface were stained and counted. Invasive ability is expressed as number of invaded cells. 
Values represent the average of triplicate experiments ± SD. E: The cells were treated with 
increasing doses of Cisplatin or Staurosporine and counted after 24 h. The percentage of 
viability inhibition is shown: values represent the average of three independent experiments ± 
SD. F: CAL62 shLUC mp and CAL62 shTWIST1 mp cells were seeded in soft agar. Total 
number of colonies were counted after 14 days: values represent the average of three 
independent experiments ± SD. Asterisks indicate p < 0.05 (*), p < 0.01 (**) and p < 0.001 
(***). 
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Figure 4: Expression levels of p53 in human thyroid cell lines. Cells were lysed and 
blotted with the indicated antibodies. 
 
 
 
TWIST1 transcription factor in thyroid tumour progression 
JCEM 10-1182 v2 
 
 10 
 
Supplemental References 
1. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin 
JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic 
acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination 
resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 
93:4331-4341 
2. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag 
G, Santoro M, Salvatore G 2010 Cytostatic activity of adenosine triphosphate-
competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin 
Endocrinol Metab 95:450-455 
3. Curcio F, Ambesi-Impiombato FS, Perrella G, Coon HG 1994 Long-term culture 
and functional characterization of follicular cells from adult normal human thyroids. 
Proc Natl Acad Sci U S A 91:9004–9008  
4. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G 1987 One- 
and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol 
Cell Biol 7:3365-3370 
5. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, 
Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 
2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and 
mitogenic phenotype of thyroid cancer cells. J Clin Invest115: 1068-1081 
TWIST1 transcription factor in thyroid tumour progression 
JCEM 10-1182 v2 
 
 11 
 
Table 1: Clinico-pathological features of anaplastic thyroid carcinoma and TWIST1 
expression. 
 
Features TWIST1 negative (n=21) TWIST1 positive (n=20) p-value 
        
Phenotype       
Epithelioid (n=19) 76% (16/21) 15% (3/20) 0.0001 
Mixed (n=7) 9% (2/21) 25% (5/20)   
Fusocellular (n=15) 15% (3/21) 60% (12/20)   
        
Ki67/MIB1 expression       
+++ (n=9) 10% (2/21) 35% (7/20) 0.048 
++ (n=16) 33% (7/21) 45% (9/20)   
+ (n=15) 52% (11/21) 20% (4/20)  
Negative (n=1) 5% (1/21) 0% (0/20)   
        
p53 expression       
+++ (n=14) 19% (4/21) 50% (10/20) 0.030 
++ (n=10) 33% (7/21) 15% (3/20)   
+ (n=5) 5% (1/21) 20% (4/20)   
Negative (n=12) 43% (9/21) 15% (3/20)   
 
+: ≥5–≤25% of positive cells 
++: >25–<60%  of positive cells 
+++:≥60% of positive cells 
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Abstract 
Medullary thyroid carcinoma (MTC), a malignancy of the parafollicular C cells of the 
thyroid gland, accounts for approximately 5% of all thyroid cancers and presents either 
sporadically (80% of patients) or in a hereditary pattern. The 10-year overall survival rate 
in unselected patients with MTC is approximately 75%, but it decreases to 40% or less in 
patients with locally advanced or metastatic disease. Germline mutations in the RET 
proto-oncogene occur in virtually all patients with hereditary MTC. Approximately 50% 
of patients with sporadic MTC have somatic RET mutations. Thus, RET is a potential 
therapeutic target in MTC. Monoclonal antibodies (mAbs) are important therapeutic 
agents for cancer. Here, we describe the generation of a panel of mAbs directed against 
the extracellular portion of RET. The mAbs were characterized by their ability to bind 
RET wild type and RET mutant proteins by ELISA, dot blot, flow cytometry and 
immunoprecipition. The mAbs were grouped on the basis of their epitope by ELISA. 
Further three mAbs named R10, R50 and R25, recognizing three different regions of the 
extracellular domain of RET, were selected and tested for their biological effects. R10, 
R25 and R50 were able to downregulate RET protein in the human medullary thyroid 
carcinoma cell lines TT and MZ-CRC-1. The downregulation of RET protein was 
followed by internalization in the early and late endosome as demonstrated by confocal 
microscopy. This, in turn translate with a cytostatic effects of the mAbs on the growth of 
NIH3T3 cells transfected with RET mutant proteins, and in the human medullary thyroid 
carcinoma TT and MZ-CRC-1 cell lines while no effects was seen in cells negative for 
RET. 
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INTRODUCTION 
 
Medullary thyroid carcinoma (MTC) arises from parafollicular C cells, comprises ~5% of 
thyroid cancers, and presents in hereditary (~20% of cases) or sporadic (~80% of MTC 
cases) forms (Kloos, 2009). The hereditary form of MTC is associated with multiple 
endocrine neoplasia type 2 (MEN2), including MEN2A, MEN2B, and familial MTC. 
Germline activating mutations in RET are the cause of inherited forms of MTC and 
somatic mutations in RET can be found in 30-50% of cases of sporadic MTC. The RET 
proto-oncogene, codes for a transmembrane receptor that has tyrosine kinase activity. 
RET is a component of a cell-surface complex that binds glial-derived neurotrophic 
factor family ligands (GDNF, neurturin, artemin and persephin) in conjunction with a 
group of coreceptors designated ‘‘GDNF-family receptor-a’’(GFRa1–4). Somatic RET 
mutations, particularly M918T, are found in about half of sporadic MTC (Schlumberger, 
2008) and correlate with an aggressive disease behavior (Elisei, 2008). MTC-associated 
mutations activate the RET kinase and convert RET into a dominantly transforming 
oncogene. Mutated RET in MTC activates several downstream signaling pathways, 
including the Ras/Raf/Mek/Erk and PI3K (phosphatidylinositol 3-kinase)/Akt/mTor 
cascades resulting in cancer development and perhaps progression.                                 
For MTC limited to the neck, surgery and in some cases external radiation therapy allow 
for either cure or disease control in the majority of patients. However, for patients with 
progressive distant metastases chemotherapy regimens have proven largely ineffective, 
indicating the need for alternative therapies.  
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One approach that recently has been studied with exciting results is to target the 
constitutively active RET kinase and/or its key downstream signaling pathways (Wells, 
2009; Ye, 2010). 
 Various RET kinase inhibitors are in clinical trials (Carlomagno, 2011). Vandetanib 
(ZD6474), an orally bioavailable anilinoquinazoline, potently inhibits the RET kinase 
(IC50=100 nM). It is also effective against VEGFR2/KDR (IC50=40 nM), EGFR 
(IC50=500 nM) and VEGFR. Vandetanib, has recently filed for FDA approval in 
metastatic/locally advanced MTC.  
Recently, large-scale genome sequencing revealed a few RET somatic mutations in colon 
cancer samples (http://www.sanger.ac.uk/genetics/CGP/cosmic/). Altered RET 
expression, rather than structural alterations, has been described in other tumor types, 
such as neuroblastomas, seminomas, pancreatic and breast carcinomas, myeloid leukemia 
(Morandi, 2011). 
 Beside kinase inhibitors, another promising therapeutic approaches to treat cancer is the 
use of monoclonal antibodies (mAbs). Due to their intrinsic specificity, mAbs represent 
one of the most promising avenues for the so-called "targeted therapy" of cancer when 
directed against specific oncogene products. As "targeting drugs," mAbs may have 
features superior to small-molecule inhibitors. These include very high specificity, 
generally constant pharmacokinetic properties in different individuals, and the fact that 
they exert therapeutic effects through a wide spectrum of biological responses. mAbs, 
intefering with functional cell-surface molecules, such as receptors, can alter different 
intracellular pathways, thus interfering with the cancer cell biology. Moreover, through 
interaction with the body's immune system, mAbs can recruit effector functions for 
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antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity. Many 
small-molecule agents and mAbs that target growth-factor receptors and their signalling 
pathways have been developed and subjected to clinical trials.  
Here, we report the generation of a panel of novel mAbs against the extracellular portion 
of RET that could be used for the target therapy of MTC or of other tumors 
overexpressing RET. 
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MATERIAL AND METHODS 
 
Generation of mAbs- The extracellular domain of the human RET was expressed as a 
fusion protein with rabbit IgG Fc in HEK 293T cells. Mice (6-8 weeks old) were 
immunized four times with the pcDNA3 RET plasmid intradermally (50 µg in 50 µL 
PBS) with 2-week intervals, and one boost was given with the RET-Fc i.p. (50 µg in 100 
µL of PBS) before fusion. Spleens were harvested 84 to 90 hours after the last boost for 
cell fusion. All animals were maintained in accordance with institutional guidelines. Cell 
fusions of the splenocytes and the SP2/0 cells were carried out according to the standard 
fusion protocol. Fourteen days after fusion, the supernatants were harvested and screened 
for antibody production by ELISA. The selected hybridomas were grown in a CELLINE 
flask (INTEGRA Biosciences, Chur, Switzerland) and purified on a protein A column 
(Amersham Biosciences). 
 
ELISA- Screening of hybridomas was done by ELISA on RET-Fc (wild type and 
mutant) fusion proteins. Briefly, Nunc-Immuno plates (Nalge Nunc International, 
Rochester, NY) were coated with 2 µg/mL of RET-Fc protein. Plates were incubated 
overnight at 4°C. Then plates were blocked in blocking buffer (PBS with 25% DMEM, 
5% FCS, 25 mmol/L HEPES, 0.5% bovine serum albumin, and 0.1% Azide) for 30 
minutes at room temperature, washed twice with washing buffer (PBS with 0.05% Tween 
20), and incubated with 100 µL supernatant of hybridoma for 1 hour at room 
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temperature. After washing, plates were incubated with a horseradish peroxidase–
conjugated goat anti-mouse antibody diluted 1:2,000 in blocking buffer. Finally, plates 
were washed with washing buffer and 100 µL immunopure tetramethylbenzidine 
substrate solution (Pierce) was added to each well. The color was allowed to develop for 
2 to 5 minutes at room temperature and the reaction stopped by the addition of 50 µL 2 N 
solution of sulfuric acid. The plates were read at OD 450 nm using an automated plate 
reader (Molecular Devices Corp., Sunnyvale, CA). 
 
Isotyping-The isotype of selected mAbs was determined using a mouse immunoglobulin 
isotyping kit (Roche Applied Science, Indianapolis, IN). 
 
Immunoblotting Analysis- Briefly, mouse fibroblasts and human thyroid carcinoma 
cells were lysed in a buffer containing 50 mM HEPES (pH 7.5), 1% (vol/vol) Triton X-
100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM 
sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, and aprotinin at 1 µg/mL. 
Lysates were clarified by centrifugation at 10 000 x g for 15 minutes. Protein lysates 
containing comparable amounts of proteins, estimated by a modified Bradford assay 
(Bio-Rad, Munich, Germany), were subjected to immunoprecipitation or direct Western 
blot. Immunocomplexes were detected with the enhanced chemiluminescence kit (Pierce 
Biotechnology Inc, Rockford, USA). Monoclonal anti-α-tubulin was from Sigma 
Chemical Co. (St. Louis, MO, USA). Anti-RET is a polyclonal antibody raised against 
the tyrosine kinase protein fragment of human RET (Carlomagno, 2002). Anti-
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phospho905 is a phospho-specific polyclonal antibody that recognizes RET proteins that 
are phosphorylated at Y905.  
 
Cell cultures- TT cells were purchased from American Type Culture Collection 
(Manassas, VA). TT cells were derived from the primary tumor of an apparently sporadic 
MTC (Leong et al. 1981). TT harbor a cysteine 634 to tryptophan (C634W) exon 11 RET 
mutation as well as a tandem duplication of the mutated RET allele (Huang et al. 2003). 
The TT cell line, was cultured in RPMI-1640 with 20% fetal calf serum, 2 mM L-
glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). MZ-CRC-1 cells were 
kindly provided by Robert F. Gagel. MZ-CRC-1 were derived from a malignant pleural 
effusion from a patient with a metastatic MTC. MZ-CRC-1 cells revealed a heterozygous 
(ATG to ACG) transition in RET exon 16 resulting in the MEN2B-associated substitution 
of threonine 918 for methionine (M918T). Parental murine NIH3T3 fibroblasts and 
NIH3T3 cells stably transfected with the RET mutants RET/C634R (MEN 2A), and 
RET/M918T (MEN 2B)), or wild-type RET are described elsewhere. Cells were cultured 
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% calf serum, 2 
mM L-glutamine, and penicillin-streptomycin at 100 units/mL of (GIBCO, Paisley, PA). 
The TPC-1 cell line, derived from a papillary thyroid carcinoma harboring the 
RET/PTC1 rearrangement, was cultured in DMEM with 10% fetal calf serum, 2 mM L-
glutamine, and penicillin-streptomycin at 100 units/mL).  
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Growth Curves- Cells (∼ 50000/dish) were seeded in 60-mm dishes. The next day, R10, 
R25 or R50 (40 µg/ml) or vehicle was added to the medium and changed every 2 days. 
Cells were counted every 2 days. 
 
Immunofluorescence- Cells were treated with R10, R25, or R50 (40 µg/ml) or vehicle at 
4°C or at 37°C for different time points. Then cells were fixed in 4% paraformaldeyde 
and permeabilized with 0.2% Triton X-100 (5 min on ice), and then incubated with α-
RET (Carlomagno, 2002) or α-EEA1 (Santa Cruz) or α-LAMP1 (Sigma) for 1 h at RT. 
Coverslips were washed and incubated with Alexa-488 Goat anti-rabbit (Invitrogen) for 
30 min at RT. After 5 min DAPI (4',6-diamidino-2-phenylindole) counterstaining, 
coverslips were mounted and observed with a Zeiss LSM 510 META confocal 
microscope (Carl Zeiss, Thornwood, NY).  
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RESULTS 
 
Generation of new RET mAbs 
To obtain mAbs that recognize the extracellular domain of RET we used a DNA 
immunization protocol followed by protein immunization for the final boost prior to cell 
fusion. The RET-Fc protein used for immunization and screening was prepared from the 
medium of transfected HEK293T cells by purification on protein A-Sepharose. Mice 
were injected intradermally with DNA prepared from the plasmid, pcDNA3-RET. Blood 
was collected from the mice after multiple injections and the antibody titer was 
determined by ELISA on plates coated with RET-Fc protein (data not shown). The two 
mice with the highest titer were sacrificed. Spleen cells from each mouse were fused to 
myeloma cells following standard procedures (Salvatore, 2002). Supernatants from 
clones of hybridoma cells were screened using ELISA. To determine the specificity of 
the antibodies, the screening was done on plates coated with RET wild type-Fc, RET 
mutant-Fc and CD30-Fc. The latter is a negative control that excludes antibodies reacting 
with the Fc portion of the fusion. Finally, 52 hybridomas were identified that reacted 
selectively with RET-Fc and not with CD30-Fc (Figure 1). The isotype of each of the 52 
mAb was determined: 33 IgG2a, 9 IgG2b and 10 IgG1 were obtained (Table1).  
We then tested the ability of the 52 supernatants ability to bind to the NIH3T3-RET-
MEN2A -expressing cell line by flow cytometry. All 52 mAbs bound to NIH3T3-RET-
MEN2A cells but did not bind to the parental NIH3T3 negative cells (data not shown).  
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Epitope mapping of RET mAbs 
 The extracellular RET domain, contains a signal peptide, four cadherin-like repeats 
(CLD1-4) and a cysteine-rich domain (CYS). To determine which epitope each mAb 
recognize we performed a dot blot on proteins encoding full RET extracellular domain 
(RET ECD), RET cadherin like domain 1-3 (CLD 1-3), RET cadherin like domain 1-2 
(CLD 1-2) and as negative controls RET intracellular domain (IC) and non-related 
proteins BSA and GST. As shown in the Figure 2, mAb R23, R44, R49, R39, R42, R21, 
R10, R2, R18, R52 and R32 reacted with CLD 1-2; mAb R20, R50 and R1 reacted with 
CLD3 and mAb R5, R35, R25, 1D9, R8 and R43 reacted with CLD4- cysteine-rich 
domain.  
Three antibodies from different epitope group named R10, R25 and R50, were further 
selected. We then tested the ability of mAb R10, R25 and R50 to bind to RET directly or 
to RET GDNF complex by ELISA. As shown in Figure 3, R10 binds preferentially to 
RET when is complexes with GDNF and GDNFR; in contrast mAb R50 preferentially 
bind to RET directly, while R25 bind either RET directly or when is complexed with 
GDNF and GDNFR. As control a commercially available mAbs (AHO1482 and RnD) 
were used.  
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Biological effects of RET mAbs 
We treated TT cells harbor a cysteine 634 to tryptophan (C634W) exon 11 RET mutation 
with mAbs R25 and R50 for 6, 12, 24 and 48 hours. Then we lysed the cells and blotted 
with antibodies against RET and RET phosphorylated at tyrosine 905. As shown in 
Figure 4 mAb R25 and R50 were able to downregulate RET proteins. Similar results 
were obtained for R10 in MZ-CRC-1 cell line (data not shown). 
 
RET mAbs induces internalization in RET expressing cells 
We treated TT cells and MZ-CRC-1 with 40 ug/ml of RET mAbs R25 and R50 at 4°C 
and at 37° C for different time points (15 minutes-30 minutes and 6 hours)- and analyzed 
the cells by confocal microscopy. As shown in Figure 5, at 4°C the mAbs stained the 
cellular surface, while at 37°C RET was internalized. Furthermore, we showed that RET 
co-localize intracellularly with the lysosomal marker LAMP1 (lysosome-associated 
membrane protein 1) and with the early endosome markers (EEA1). Similary in MZC-
RC-1 cells the mAbs R25 and R50 induces RET internalization (Figure 6). 
 
Effects of RET mAbs on cellular growth 
Finally, we treated NIH3T3-RET-M918T, NIH3T3, TT and TPC-1 cells treated with 40 
µg/ml of R25 and measured cellular growth. As shown in Figure 7, mAb R25 reduced 
growth rate in the cell lines expressing mutatant RET proteins, no effects was seen in 
  13 
parental or in TPC-1 cells that express only the intracellular portion of RET. Similar 
results were obtained with mAbs R10 and R50 (data not shown). 
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Discussion 
Oncogenic activation of the RET receptor tyrosine kinase is associated with thyroid 
cancer (Kondo, 2006). Medullary thyroid carcinoma (MTC) is associated to RET gain-of-
function point mutations.  
MTC is refractory to conventional chemotherapy and radiotherapy, its treatment relying 
only on surgery. Unfortunately, postsurgical persistent disease is observed in 70-80% of 
MTC patients and recurrence rate is between 35 % and 65%. Therefore, there is a need 
for novel therapeutic approaches for this cancer. 
Several chemical inhibitors of oncogenic kinases have been isolated. In most of the cases, 
such inhibitors are small organic compounds competitive with respect to ATP (Baselga, 
2006). The paradigm is imatinib mesylate (STI571, Glivec), a BCR-ABL inhibitor active 
in chronic myeloid leukemia (CML). Unlike imatinib in CML, kinase inhibitors, when 
used as single agents, have yielded modest clinical success in patients with solid tumors. 
Recently, small molecule inhibitors for the RET kinase have also been identified 
(Carlomagno, 2011).  
Scientific exploration of cancer immunotherapy began in the 1950s and the first 
application relied on polyclonal antibodies. Today, after more than five decades, 
immunotherapy with monoclonal antibodies continues to offer a promising alternative for 
cancer treatment. Several antibodies targeting tyrosine kinase receptors (RTKs) in cancer 
are currently used in clinical practice. Putative mechanisms of mAb-based cancer therapy 
can be classified into two categories. The first is direct action, which can be further 
subcategorized into three modes of action. One mode of action is blocking the function of 
target signalling molecules or receptors. This can occur by blocking ligand binding, 
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inhibiting cell-cycle progression or DNA repair, inducing the regression of angiogenesis, 
increasing the internalization of receptors or reducing proteolytic cleavage of receptors. 
Other modes of direct action are stimulating function, which induces apoptosis, and 
targeting function. The second mechanism of mAb therapy is indirect action mediated by 
the immune system. The elimination of tumour cells using mAbs depends on Ig-mediated 
mechanisms, including complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC), to activate immune-effector cells. Thus, the 
generation of mAbs targeting RET can yield to several advantages compared to kinase 
inhibitors. Further studies are on going, to validate the efficacy of the mAbs in vivo in 
nude mice.  
In conclusion, here we have generated a panel of mAbs that downregulate RET protein, 
and reduce the growth of thyroid cancer cells positive for RET. The generation of mAbs 
targeting RET could be beneficial not only for MTC but also for the other human tumors 
overexpressing RET. 
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Figures legend 
 
Figure 1: Screening of hybridoma supernatants by ELISA.  
Supernatants of the 52 Mabs were screened against wild type RET-Fc,  mutant RET 
(C634R)-Fc or CD30-Fc in solution or coated on plate. The 1D9 and 2D6 supernatants 
were used as control. T6 and T25 are antibody against CD30. 
 
Figure 2: Proteins encoding the RET extracellular domain (RET ECD), RET cadherin 
like domain 1-3 (CLD 1-3), RET cadherin like domain 1-2 (CLD 1-2) and as negative 
controls RET intracellular domain (IC) and non-related proteins BSA and GST were 
coated on nitrocellulose paper and blotted with the indicated supernatants. 
 
Figure 3: ELISA was performed with R10, R25 and R50 or controls on RET protein or 
on GDNF+GFRA1or blank control. 
 
Figure 4: NIH3T3-RET/MEN2A cell were treated for 48 hours with 40 µg/ml of R25 
Mab. Cell lysates (50 µg) were immunoblotted with anti RET (polyclonal antibody 
directed to the tyrosine portion of RET) or with anti phospho-RET (tyrosine 905). Anti 
tubulin stain show equal gel loading.  
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Figure 5: TT cells were incubated with R25 or R50 at a concentration of 40 µg/ml at the 
indicated time points. Immunufluorescence was performed with anti RET, anti EEA1 or 
anti LAMP1. 
 
Figure 6: MZ-CRC-1 cells were incubated with R25 or R50 at a concentration of 40 
µg/ml at the indicated time points. Immunufluorescence was performed with anti RET, 
anti EEA1 or anti LAMP1 antibodies. 
 
Figure 7: The indicated cell lines were treated with 40 µg/ml of R25 mAb at different 
time points and counted.  
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 Table 1: List of RETmAbs and their isotype. 
 
mAb Isotype 
R1 IgG2a 
R2 IgG2b 
R3 IgG2a 
R4 IgG2a 
R5 IgG2b 
R6 IgG2a 
R7 IgG2b 
R8 IgG1 
R9 IgG2a 
R10 IgG1 
R11 IgG2a 
R12 IgG2a 
R39 IgG1 
R40 IgG2a 
R42 IgG1 
R43 IgG1 
R44 IgG2b 
R45 IgG1 
R46 IgG2b 
R47 IgG2a 
R48 IgG2a 
R49 IgG2b 
R50 IgG2a 
R51 IgG2a 
R52 IgG2a 
R53 IgG2a 
 
 







